<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T04:06:08Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:6507192" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:6507192</identifier>
        <datestamp>2019-05-13</datestamp>
        <setSpec>jaha</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">J Am Heart Assoc</journal-id>
              <journal-id journal-id-type="iso-abbrev">J Am Heart Assoc</journal-id>
              <journal-id journal-id-type="doi">10.1002/(ISSN)2047-9980</journal-id>
              <journal-id journal-id-type="publisher-id">JAH3</journal-id>
              <journal-id journal-id-type="hwp">ahaoa</journal-id>
              <journal-title-group>
                <journal-title>Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease</journal-title>
              </journal-title-group>
              <issn pub-type="epub">2047-9980</issn>
              <publisher>
                <publisher-name>John Wiley and Sons Inc.</publisher-name>
                <publisher-loc>Hoboken</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC6507192</article-id>
              <article-id pub-id-type="pmcid">PMC6507192</article-id>
              <article-id pub-id-type="pmc-uid">6507192</article-id>
              <article-id pub-id-type="pmid">30943832</article-id>
              <article-id pub-id-type="pmid">30943832</article-id>
              <article-id pub-id-type="doi">10.1161/JAHA.119.011961</article-id>
              <article-id pub-id-type="publisher-id">JAH33961</article-id>
              <article-categories>
                <subj-group subj-group-type="overline">
                  <subject>Original Research</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>Original Research</subject>
                  <subj-group subj-group-type="heading">
                    <subject>Hypertension</subject>
                  </subj-group>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Prevention of Heart Failure in Hypertension—Disentangling the Role of Evolving Left Ventricular Hypertrophy and Blood Pressure Lowering: The <styled-content style="fixed-case">ALLHAT</styled-content> Study</article-title>
                <alt-title alt-title-type="left-running-head">Johnson et al</alt-title>
              </title-group>
              <contrib-group>
                <contrib id="jah33961-cr-0001" contrib-type="author">
                  <name>
                    <surname>Johnson</surname>
                    <given-names>Kyle</given-names>
                  </name>
                  <degrees>BS</degrees>
                  <xref ref-type="aff" rid="jah33961-aff-0001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="jah33961-cr-0002" contrib-type="author">
                  <name>
                    <surname>Oparil</surname>
                    <given-names>Suzanne</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="jah33961-aff-0002">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="jah33961-cr-0003" contrib-type="author">
                  <name>
                    <surname>Davis</surname>
                    <given-names>Barry R.</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                  <xref ref-type="aff" rid="jah33961-aff-0003">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib id="jah33961-cr-0004" contrib-type="author" corresp="yes">
                  <name>
                    <surname>Tereshchenko</surname>
                    <given-names>Larisa G.</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                  <address>
                    <email>tereshch@ohsu.edu</email>
                  </address>
                  <xref ref-type="aff" rid="jah33961-aff-0001">
                    <sup>1</sup>
                  </xref>
                </contrib>
              </contrib-group>
              <aff id="jah33961-aff-0001">
                <label>
                  <sup>1</sup>
                </label>
                <institution>The Knight Cardiovascular Institute</institution>
                <institution>Oregon Health &amp; Science University</institution>
                <named-content content-type="city">Portland</named-content>
                <named-content content-type="country-part">OR</named-content>
              </aff>
              <aff id="jah33961-aff-0002">
                <label>
                  <sup>2</sup>
                </label>
                <named-content content-type="organisation-division">Department of Medicine</named-content>
                <named-content content-type="organisation-division">School of Medicine</named-content>
                <institution>University of Alabama at Birmingham</institution>
                <named-content content-type="country-part">AL</named-content>
              </aff>
              <aff id="jah33961-aff-0003">
                <label>
                  <sup>3</sup>
                </label>
                <institution>University of Texas School of Public Health</institution>
                <named-content content-type="city">Houston</named-content>
                <named-content content-type="country-part">TX</named-content>
              </aff>
              <author-notes>
                <corresp id="correspondenceTo"><label>*</label><bold>Correspondence to:</bold> Larisa G. Tereshchenko, MD, PhD, 3181 SW Sam Jackson Park Rd, UHN62, Portland, OR 97239. E‐mail: <email>tereshch@ohsu.edu</email></corresp>
              </author-notes>
              <pub-date pub-type="epub">
                <day>04</day>
                <month>4</month>
                <year>2019</year>
              </pub-date>
              <pub-date pub-type="collection">
                <day>16</day>
                <month>4</month>
                <year>2019</year>
              </pub-date>
              <volume>8</volume>
              <issue>8</issue>
              <issue-id pub-id-type="doi">10.1002/jah3.2019.8.issue-8</issue-id>
              <elocation-id>e011961</elocation-id>
              <history>
                <date date-type="received">
                  <day>05</day>
                  <month>1</month>
                  <year>2019</year>
                </date>
                <date date-type="accepted">
                  <day>19</day>
                  <month>2</month>
                  <year>2019</year>
                </date>
              </history>
              <permissions>
                <!--<copyright-statement content-type="issue-copyright"> Copyright &#x000a9; 2019 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell <copyright-statement>-->
                <copyright-statement content-type="article-copyright">© 2019 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.</copyright-statement>
                <license license-type="creativeCommonsBy-nc-nd">
                  <license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:type="simple" xlink:href="file:JAH3-8-e011961.pdf"/>
              <abstract id="jah33961-abs-0001">
                <sec id="jah33961-sec-0001">
                  <title>Background</title>
                  <p>Hypertension is a known risk factor for heart failure (<styled-content style="fixed-case">HF</styled-content>), possibly via the mechanism of cardiac remodeling and left ventricular hypertrophy (<styled-content style="fixed-case">LVH</styled-content>). We studied the extent to which blood pressure (<styled-content style="fixed-case">BP</styled-content>) change and evolving <styled-content style="fixed-case">LVH</styled-content> contribute to the effect that lisinopril, doxazosin, and amlodipine have on <styled-content style="fixed-case">HF</styled-content> compared with chlorthalidone.</p>
                </sec>
                <sec id="jah33961-sec-0002">
                  <title>Methods and Results</title>
                  <p>We conducted causal mediation analysis of <styled-content style="fixed-case">ALLHAT</styled-content> (Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial) data (1994‐2002; in‐trial follow‐up). <styled-content style="fixed-case">ALLHAT</styled-content> participants with available serial <styled-content style="fixed-case">ECG</styled-content>s and <styled-content style="fixed-case">BP</styled-content> measurements were included (n=29 892; mean age 67±4 years; 32% black; 56% men): 11 008 were randomized to chlorthalidone, 5967 to doxazosin, 6593 to amlodipine, and 6324 to lisinopril. Evolving <styled-content style="fixed-case">ECG LVH</styled-content> and <styled-content style="fixed-case">BP</styled-content> lowering served as mediators. Incident symptomatic <styled-content style="fixed-case">HF</styled-content> was the primary outcome. Linear regression (for mediator) and logistic regression (for outcome) models were adjusted for mediator‐outcome confounders (demographic and clinical characteristics known to be associated both with both <styled-content style="fixed-case">LVH</styled-content>/hypertension and <styled-content style="fixed-case">HF</styled-content>). A large majority of participants (96%) had <styled-content style="fixed-case">ECG LVH</styled-content> status unchanged, but 4% developed evolving <styled-content style="fixed-case">ECG LVH</styled-content>. On average, <styled-content style="fixed-case">BP</styled-content> decreased by 11/7 mm Hg. In adjusted Cox regression analyses, progressing <styled-content style="fixed-case">ECG LVH</styled-content> (hazard ratio [<styled-content style="fixed-case">HR</styled-content>] 1.78 [95% CI 1.43‐2.22]), resolving <styled-content style="fixed-case">ECG LVH</styled-content> (<styled-content style="fixed-case">HR</styled-content> 1.33 [95% CI 1.03‐1.70]), and baseline <styled-content style="fixed-case">ECG LVH</styled-content> (1.17 [95% CI 1.04‐1.31]) carried risk of incident <styled-content style="fixed-case">HF</styled-content>. After full adjustment, evolving <styled-content style="fixed-case">ECG LVH</styled-content> mediated 4% of the effect of doxazosin on <styled-content style="fixed-case">HF</styled-content>. Systolic <styled-content style="fixed-case">BP</styled-content> lowering mediated 12% of the effect of doxazosin, and diastolic <styled-content style="fixed-case">BP</styled-content> lowering mediated 10% of the effect of doxazosin, 7% of the effect of amlodipine, and borderline 9% of the effect of lisinopril on <styled-content style="fixed-case">HF</styled-content>.</p>
                </sec>
                <sec id="jah33961-sec-0003">
                  <title>Conclusions</title>
                  <p>Evolving <styled-content style="fixed-case">ECG LVH</styled-content> and <styled-content style="fixed-case">BP</styled-content> change account for 4% to 13% of the mechanism by which antihypertensive medications prevent <styled-content style="fixed-case">HF</styled-content>.</p>
                </sec>
                <sec id="jah33961-sec-0004">
                  <title>Clinical Trial Registration</title>
                  <p><styled-content style="fixed-case">URL</styled-content>: <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov">http://www.clinicaltrials.gov</ext-link>. Unique identifier: <styled-content style="fixed-case">NCT</styled-content>00000542.</p>
                </sec>
              </abstract>
              <abstract abstract-type="short" id="jah33961-abs-0002">
                <p>See Editorial <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1161/JAHA.119.012457">Ferdinand and Maraboto</ext-link>
</p>
              </abstract>
              <kwd-group kwd-group-type="author-generated">
                <kwd id="jah33961-kwd-0001">antihypertensive agent</kwd>
                <kwd id="jah33961-kwd-0002">
                  <styled-content style="fixed-case">ECG</styled-content>
                </kwd>
                <kwd id="jah33961-kwd-0003">heart failure</kwd>
                <kwd id="jah33961-kwd-0004">hypertension</kwd>
                <kwd id="jah33961-kwd-0005">left ventricular hypertrophy</kwd>
              </kwd-group>
              <kwd-group kwd-group-type="subject-categories">
                <title>Subject Categories</title>
                <kwd>Heart Failure</kwd>
                <kwd>Hypertrophy</kwd>
                <kwd>Hypertension</kwd>
                <kwd>Treatment</kwd>
              </kwd-group>
              <funding-group>
                <award-group>
                  <funding-source>National Heart, Lung, and Blood Institute</funding-source>
                  <award-id>NO1‐HC‐35130</award-id>
                  <award-id>HL118277</award-id>
                </award-group>
                <award-group>
                  <funding-source>Pfizer</funding-source>
                </award-group>
                <award-group>
                  <funding-source>AstraZeneca</funding-source>
                </award-group>
                <award-group>
                  <funding-source>Bristol‐Myers Squibb</funding-source>
                </award-group>
              </funding-group>
              <counts>
                <fig-count count="7"/>
                <table-count count="5"/>
                <page-count count="15"/>
                <word-count count="9486"/>
              </counts>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>source-schema-version-number</meta-name>
                  <meta-value>2.0</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>component-id</meta-name>
                  <meta-value>jah33961</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>cover-date</meta-name>
                  <meta-value>16 April 2019</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>details-of-publishers-convertor</meta-name>
                  <meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:5.6.2.1 mode:remove_FC converted:16.04.2019</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
            <notes>
              <p content-type="self-citation">
                <mixed-citation publication-type="journal" id="jah33961-cit-1001">(<source xml:lang="en">J Am Heart Assoc</source>. <year>2019</year>;<volume>8</volume>:<elocation-id>e011961</elocation-id> DOI: <pub-id pub-id-type="doi">10.1161/JAHA.119.011961</pub-id>.)<pub-id pub-id-type="pmid">30943832</pub-id></mixed-citation>
              </p>
            </notes>
          </front>
          <body>
            <p>
              <boxed-text position="anchor" content-type="box" id="jah33961-blkfxd-0001" orientation="portrait">
                <sec id="jah33961-sec-0006">
                  <title>Clinical Perspective</title>
                  <sec id="jah33961-sec-0007">
                    <title>What Is New?</title>
                    <p>
                      <list list-type="bullet" id="jah33961-list-0001">
                        <list-item>
                          <p>Patients with progressing and resolving left ventricular hypertrophy (LVH), as measured by serial ECGs, show an increase in heart failure risk compared with those with no evolving ECG LVH.</p>
                        </list-item>
                        <list-item>
                          <p>There is a U‐shaped association of blood pressure lowering and incident heart failure in which both greater increases and decreases in blood pressure over time are associated with an increased risk of heart failure.</p>
                        </list-item>
                      </list>
                    </p>
                  </sec>
                  <sec id="jah33961-sec-0008">
                    <title>What Are the Clinical Implications?</title>
                    <p>
                      <list list-type="bullet" id="jah33961-list-0002">
                        <list-item>
                          <p>Hypertension and LVH are some of the pathways that can lead to heart failure, but simply trying to reverse these maladaptive pathways does not substantially improve mortality or symptoms from heart failure.</p>
                        </list-item>
                        <list-item>
                          <p>The protective effect of antihypertensive medications on heart failure is largely due to mechanisms outside of blood pressure lowering and evolving ECG LVH.</p>
                        </list-item>
                        <list-item>
                          <p>Although improving hypertension control and reducing/preventing LVH are clinically important, other aspects of cardiac health should be emphasized in order to lower risk of heart failure.</p>
                        </list-item>
                      </list>
                    </p>
                  </sec>
                </sec>
              </boxed-text>
            </p>
            <sec id="jah33961-sec-0009">
              <title>Introduction</title>
              <p>Hypertension (HTN) is a major risk factor for heart failure (HF).<xref rid="jah33961-bib-0001" ref-type="ref">1</xref> HTN triggers cardiac remodeling and development of left ventricular hypertrophy (LVH), leading to subclinical organ damage, which evolves to clinically manifest HF and, ultimately, to death.<xref rid="jah33961-bib-0002" ref-type="ref">2</xref> The beneficial effect of antihypertensive treatment on HF risk is well known<xref rid="jah33961-bib-0003" ref-type="ref">3</xref> and reflected in the 2017 American College of Cardiology/American Heart Association Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults.<xref rid="jah33961-bib-0004" ref-type="ref">4</xref> HTN treatment is associated with an ≈20% to 25% reduction in risk of incident HF.<xref rid="jah33961-bib-0005" ref-type="ref">5</xref>
</p>
              <p>ALLHAT (the Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial)<xref rid="jah33961-bib-0006" ref-type="ref">6</xref> was a multicenter, randomized, double‐blind, active‐controlled trial designed to compare cardiovascular outcomes in high‐risk antihypertensive patients assigned to the angiotensin‐converting enzyme inhibitor lisinopril, the calcium channel blocker amlodipine, and the α‐blocker doxazosin, in comparison to a thiazide‐type diuretic (chlorthalidone). Incident HF was a prespecified ALLHAT outcome. The rationale for the ALLHAT hypothesis was based on the previous demonstrations that angiotensin‐converting enzyme inhibitors and calcium channel blockers are more effective than diuretics in reducing left ventricular (LV) mass index measured by echocardiography.<xref rid="jah33961-bib-0007" ref-type="ref">7</xref> Contrary to expectations, the ALLHAT showed that chlorthalidone was superior to amlodipine, lisinopril, and doxazosin in preventing HF.<xref rid="jah33961-bib-0008" ref-type="ref">8</xref>, <xref rid="jah33961-bib-0009" ref-type="ref">9</xref> The subsequent ALLHAT HF validation study reinforced the original ALLHAT results.<xref rid="jah33961-bib-0010" ref-type="ref">10</xref>, <xref rid="jah33961-bib-0011" ref-type="ref">11</xref>, <xref rid="jah33961-bib-0012" ref-type="ref">12</xref>
</p>
              <p>Although ALLHAT answered questions about the comparative effectiveness of antihypertensive treatments for HF prevention, the mechanisms behind this HF prevention remain incompletely understood. The extent to which the effect of a calcium channel blocker, an angiotensin‐converting enzyme inhibitor, and an α‐blocker (as compared with a diuretic) on incident HF is mediated by evolving LVH and blood pressure (BP) lowering per se remains unknown. This study aimed to quantify the extent to which the effects of lisinopril, amlodipine, and doxazosin (as compared with chlorthalidone) on incident HF are mediated by evolving LVH and BP lowering. We hypothesized that evolving ECG LVH and BP lowering are mechanisms behind previously observed differences in the rate of incident HF in hypertensive ALLHAT participants randomized to lisinopril, amlodipine, and doxazosin in comparison to those randomized to chlorthalidone.</p>
            </sec>
            <sec id="jah33961-sec-0010">
              <title>Methods</title>
              <p>For this study we used the ALLHAT data set, publicly available from the National Heart, Lung, and Blood Institute, via the Biologic Specimen and Data Repository Information Coordinating Center. The study was reviewed by an Oregon Health and Science University Institutional Review Board, which determined that it did not require further review due to the deidentified nature of the publicly available data set.</p>
              <sec id="jah33961-sec-0011">
                <title>Study Population</title>
                <p>The ALLHAT design and rationale have been described previously.<xref rid="jah33961-bib-0006" ref-type="ref">6</xref> Briefly, ALLHAT was conducted from 1994 to 2002 and enrolled adults age 55 and above with HTN and at least 1 risk factor (documented coronary heart disease [CHD], type 2 diabetes mellitus, LVH on ECG or echocardiogram, smoking, high‐density lipoprotein &lt;35 mg/dL, or ST‐T ECG changes indicative of ischemia). Symptomatic HF patients or those with LV ejection fraction &lt;35%, patients with recent myocardial infarction (MI), stroke, or poorly controlled HTN were excluded.</p>
                <p>In this study we included ALLHAT participants with available assessment of evolving LVH status and dynamic BP changes during in‐trial follow‐up. We excluded participants with missing covariates. The final study population included 29 892 participants: 11 008 were randomized to chlorthalidone, 5967 to doxazosin, 6593 to amlodipine, and 6324 to lisinopril (Figure <xref rid="jah33961-fig-0001" ref-type="fig">1</xref>).</p>
                <fig fig-type="Figure" xml:lang="en" id="jah33961-fig-0001" orientation="portrait" position="float">
                  <label>Figure 1</label>
                  <caption>
                    <p>Flow diagram of exclusion criteria applied to achieve the final study population for this secondary analysis of ALLHAT (Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial) data. BP indicates blood pressure; LVH, left ventricular hypertrophy; ITT, intention to treat.</p>
                  </caption>
                  <graphic id="nlm-graphic-1" xlink:href="JAH3-8-e011961-g001"/>
                </fig>
              </sec>
              <sec id="jah33961-sec-0012">
                <title>ECG Analysis: Evolving LVH During Follow‐Up</title>
                <p>ECGs were recorded at the study sites at baseline and biannually during follow‐up. Minnesota coding<xref rid="jah33961-bib-0013" ref-type="ref">13</xref> of serial ECG changes was performed in trial, from 1994 to 2002, at the Minnesota ECG‐coding core center at the University of Minnesota in Minneapolis by reviewers who were blinded to treatment assignments. LVH was examined only in clinic (nonhospital) ECG recordings. The procedure for serial ECG coding has been previously described.<xref rid="jah33961-bib-0014" ref-type="ref">14</xref> First, Minnesota prevalence codes were assigned to all ECGs. Minnesota codes 3‐1 and 3‐3 are high left R amplitude patterns (relevant to LVH) as measured on the next‐to‐last complete normal beat. Code 3‐1 was coded if any of the following 3 criteria were present: (1) R amplitude &gt;26 mm in either lead V5 or lead V6; (2) R amplitude &gt;20 mm in any of leads I, II, III, or aVF; (3) R amplitude &gt;12 mm in lead aVL. Code 3‐3 was coded if 1 or both of the following 2 criteria were present: R‐wave amplitude &gt;15 mm but ≤20 mm in lead I; R‐wave amplitude in V5 or V6 plus S or QS amplitude in V1 &gt;35 mm.</p>
                <p>Then, any specific Minnesota prevalence code change between baseline ECG and follow‐up was identified by a computer algorithm and used to select ECG pairs for direct serial comparison. Each Minnesota code change was evaluated for its importance by direct visual comparison of baseline and follow‐up waveforms and was either confirmed or not confirmed. Interobserver and intraobserver agreement was consistently high in the Minnesota coding center, as previously reported.<xref rid="jah33961-bib-0014" ref-type="ref">14</xref> The Minnesota code allowed objective classification of evolving LVH over time by setting limits to the percentage of change in voltage that occurs in serial ECGs.<xref rid="jah33961-bib-0013" ref-type="ref">13</xref> At the first step it was determined in which lead the most severe 3‐code occurred. Code 3‐1 was considered more severe than code 3‐3. If both ECGs had the same 3‐code, the follow‐up record determined which lead to use to compare with the reference ECG. If the 3‐code occurred in different leads, the following hierarchy was used to determine which lead to compare: V5/V6 (whichever R‐amplitude is higher) &gt;I&gt;II&gt;III&gt;aVL. In addition, several ECG LVH definitions were included (Sokolow‐Lyon, Cornell voltage, Cornell product, sum of 12 leads, 12‐leads product) using previously described thresholds.<xref rid="jah33961-bib-0013" ref-type="ref">13</xref> Evolving LVH was coded as either a significant progression/increase (including newly diagnosed ECG LVH) or a significant resolution/decrease (including complete resolution of ECG LVH). Absence of evolving ECG LVH was coded if the change in voltage was below the predefined threshold.<xref rid="jah33961-bib-0013" ref-type="ref">13</xref>
</p>
              </sec>
              <sec id="jah33961-sec-0013">
                <title>BP Changes During Course of the Trial</title>
                <p>BP was measured at every follow‐up visit (every 3 months for the first year and every 4 months thereafter). At each visit BP was recorded as an average of 2 measurements. To calculate achieved BP lowering during the trial, we subtracted baseline BP from the BP obtained at the latest in‐trial study visit available at year 1, 2, 3, 4, 5, or 6 from baseline, thus obtaining estimates of the “greatest” BP control. In addition, we conducted sensitivity analyses with 3 other definitions of BP lowering. By subtracting baseline BP from the BP obtained at the next in‐trial study visit available, we obtained estimates of the “fastest” BP control. We also divided the greatest and fastest BP control estimates by the baseline BP, obtaining relative greatest and fastest BP lowering.</p>
              </sec>
              <sec id="jah33961-sec-0014">
                <title>Primary Outcome: Incident Heart Failure</title>
                <p>Incident symptomatic congestive HF as defined by the ALLHAT investigators was a primary outcome in this study. Diagnosis of symptomatic congestive HF required the presence of both (1) paroxysmal nocturnal dyspnea or dyspnea at rest or New York Heart Association class III symptoms, or orthopnea and (2) rales or ankle edema (2+ or greater) or sinus tachycardia of 120 beats/min or more after 5 minutes at rest or cardiomegaly by chest x‐ray or chest x‐ray characteristic of congestive HF or S3 gallop or jugular venous distention. The incident HF outcome was validated by the ALLHAT HF validation study.<xref rid="jah33961-bib-0010" ref-type="ref">10</xref> In the current study hospitalized/fatal HF was included as a secondary outcome.</p>
              </sec>
              <sec id="jah33961-sec-0015">
                <title>Covariates</title>
                <p>Baseline BP was calculated as an average of 2 BP determinations taken at least 1 day apart, with each determination being an average of 2 measurements.</p>
                <p>Baseline ECG LVH was based on any ECG within the past 2 years. Baseline ECG LVH definition included any 1 of the following: (1) R amplitude in V5 or V6 &gt;26 mm, (2) R amplitude in V5 or V6 plus S amplitude in V1 &gt;35 mm, (3) R amplitude in aVL &gt;12 mm, (4) R amplitude in lead I &gt;15 mm, (5) R amplitude in leads II or III or aVF &gt;20 mm, (6) R amplitude in lead I plus S amplitude in lead III &gt;25 mm, (7) R amplitude in aVL plus S amplitude in V3 &gt;28 mm for men or &gt;22 mm for women, or (8) computerized ECG machine–documented LVH.</p>
                <p>Echocardiographic LVH was defined as combined wall (posterior wall plus interventricular septum) thickness ≥25 mm on any ECG in the past 2 years.</p>
                <p>Baseline medical history was determined by the study investigators by a combination of chart review and questioning during a routine office visit. HTN history determined whether participants were treated for at least 2 months, were treated for &lt;2 months, or were untreated. History of MI or stroke was at least 6 months old. History of revascularization included history of angioplasty, stenting, atherectomy, bypass surgery (coronary; peripheral vascular; carotid; vertebrobasilar), or aortic aneurysm repair. Presence of major ST‐segment depression or T‐wave elevation on any ECG in the past 2 years was identified. History of other atherosclerotic cardiovascular disease included documented peripheral artery disease or cerebrovascular disease. Baseline CHD history included known prior MI (including silent MI), angina, cardiac arrest, angiographically defined coronary stenosis more than 50%, reversible perfusion defects on cardiac scintigraphy, or prior coronary revascularization procedures. Type 2 diabetes mellitus was defined as fasting plasma glucose &gt;140 mg/dL (7.77 mmol/L) or nonfasting plasma glucose &gt;200 mg/dL (11.1 mmol/L) in the past 2 years and/or current treatment with insulin or oral hypoglycemic agents. History of high‐density lipoprotein cholesterol &lt;35 mg/dL (0.91 mmol/L) on any 2 or more determinations within the past 5 years was included. History of smoking was also obtained.</p>
              </sec>
              <sec id="jah33961-sec-0016">
                <title>Statistical Analyses</title>
                <p>All continuous variables are presented as means±SD. ANOVA and χ<sup>2</sup> test were used for unadjusted comparison of clinical characteristics in participants with evolving ECG LVH. To determine the association of clinical characteristics with achieved in‐trial BP changes, we used multivariable linear regression models, minimally adjusted for age, sex, and race/ethnicity. Intention‐to‐treat randomization assignment was used for definition of antihypertensive treatment groups.</p>
                <p>Minimally adjusted (by age, sex, and race/ethnicity) Cox regression models were used to describe associations of baseline clinical characteristics, evolving ECG LVH, and BP lowering with 2 different definitions of incident HF, for comparison. Associations between BP lowering (continuous variable) and HF risk were also evaluated using adjusted (as above) Cox regression models incorporating cubic splines with 4 knots.</p>
                <p>We conducted causal mediation analysis,<xref rid="jah33961-bib-0015" ref-type="ref">15</xref> allowing for treatment‐mediator interaction in the logistic regression, using counterfactual definitions of direct and indirect effects, as implemented by Valeri and Vanderweele.<xref rid="jah33961-bib-0016" ref-type="ref">16</xref> Two models were estimated: a linear model for the mediator conditional on treatment and covariates and a logistic model for the outcome conditional on treatment, the mediator, and covariates. Our study design was well suited for mediation analysis because randomization eliminated exposure‐outcome and exposure‐mediator confounding. Two mediators were studied (Figure <xref rid="jah33961-fig-0002" ref-type="fig">2</xref>): (1) evolving ECG LVH and (2) BP lowering over the course of the trial. We adjusted for mediator‐outcome confounders,<xref rid="jah33961-bib-0011" ref-type="ref">11</xref>, <xref rid="jah33961-bib-0017" ref-type="ref">17</xref> which were measured at baseline: demographic (age, sex, race and ethnicity) and clinical characteristics known to be associated both with LVH/HTN and HF; common risk factors (body mass index, smoking, diabetes mellitus), HTN history (levels of baseline systolic BP [SBP] and diastolic BP [DBP], baseline use of antihypertensive medications, ECG or echo LVH); CHD or cardiovascular disease history, coronary revascularization, major ST depression or T‐wave inversion, high‐density lipoprotein &lt;35 mg/dL twice in the past 5 years, and participation in the lipid‐lowering ALLHAT trial. A natural direct effect represents the influence of antihypertensive treatment that is independent of evolving ECG LVH or BP lowering in the absence of evolving ECG LVH or BP changes (eg, via pleiotropic effects or drug‐specific pharmacodynamics). A controlled direct effect represents the effect of antihypertensive drug at a certain level of mediator (at progressing/resolving ECG LVH with a reference at absent evolving ECG LVH, and at tertiles of BP changes), allowing measurement of interaction between treatment and a mediator. A mediated effect represents the influence of antihypertensive drug that can be explained by its influence on evolving ECG LVH or dynamic BP changes achieved over the course of the trial. To assess the extent of mediation, we estimated the proportion mediated as a ratio of DE×(ME−1)/(DE×ME−1), where DE is direct effect and ME is mediated effect.</p>
                <fig fig-type="Figure" xml:lang="en" id="jah33961-fig-0002" orientation="portrait" position="float">
                  <label>Figure 2</label>
                  <caption>
                    <p>Directed acyclic graph to illustrate possible structural relationships between randomized antihypertensive treatment (Rx) in intention‐to‐treat (<styled-content style="fixed-case">ITT</styled-content>) analysis evolving <styled-content style="fixed-case">ECG</styled-content> left ventricular hypertrophy (<styled-content style="fixed-case">LVH</styled-content>) (<bold>A</bold>) or blood pressure (<styled-content style="fixed-case">BP</styled-content>) lowering (<bold>B</bold>), and incident heart failure (<styled-content style="fixed-case">HF</styled-content>). <styled-content style="fixed-case">CC</styled-content> denotes common causes (confounding factors), measured and unmeasured. The mediated effect is represented by the pathway from antihypertensive Rx to incident <styled-content style="fixed-case">HF</styled-content> that goes through (<bold>A</bold>) evolving <styled-content style="fixed-case">ECG LVH</styled-content> or (<bold>B</bold>) <styled-content style="fixed-case">BP</styled-content> lowering. The direct effect is the pathway from antihypertensive Rx straight to incident <styled-content style="fixed-case">HF</styled-content>.</p>
                  </caption>
                  <graphic id="nlm-graphic-3" xlink:href="JAH3-8-e011961-g002"/>
                </fig>
                <sec id="jah33961-sec-0017">
                  <title>Sensitivity Analyses</title>
                  <p>To test the robustness of our findings, we repeated analyses with different definitions of BP lowering, expressed as (1) fastest BP control, (2) relative greatest BP control, or (3) relative fastest BP control.</p>
                  <p>Statistical analyses were performed using STATA MP 15.1 (StataCorp LLC, College Station, TX). Given the many multivariate and interaction analyses performed, statistical significance at the 0.05 level should be interpreted cautiously.</p>
                </sec>
              </sec>
            </sec>
            <sec id="jah33961-sec-0018">
              <title>Results</title>
              <sec id="jah33961-sec-0019">
                <title>Study Population</title>
                <p>The study population (Table <xref rid="jah33961-tbl-0001" ref-type="table">1</xref>) was identical to the previously reported ALLHAT population,<xref rid="jah33961-bib-0008" ref-type="ref">8</xref>, <xref rid="jah33961-bib-0009" ref-type="ref">9</xref> maintaining the treatment groups randomization ratio 1.7:1:1:1. After a median 3.1 years of follow‐up in the doxazosin group, and 5.0 years in the other 3 groups, there were 2049 incident HF outcomes, including 1598 hospitalized/fatal HF outcomes.</p>
                <table-wrap id="jah33961-tbl-0001" xml:lang="en" orientation="portrait" position="float">
                  <label>Table 1</label>
                  <caption>
                    <p>Clinical Characteristics of Study Participants With Evolving ECG LVH Increase or Decrease</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <thead valign="top">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="top" rowspan="1" colspan="1">Characteristic</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">All (n=29 892)</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">Evolving ECG‐LVH Resolution (n=718; 2.4%)</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">Absent Evolving ECG LVH (n=28 493; 95.3%)</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">Evolving ECG LVH Progression (n=681; 2.3%)</th>
                        <th align="left" valign="top" rowspan="1" colspan="1"><italic>P</italic> Value</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Age (SD), y</td>
                        <td align="left" rowspan="1" colspan="1">66.6 (7.4)</td>
                        <td align="left" rowspan="1" colspan="1">66.7 (7.7)</td>
                        <td align="left" rowspan="1" colspan="1">66.6 (7.4)</td>
                        <td align="left" rowspan="1" colspan="1">67.5 (7.8)</td>
                        <td align="left" rowspan="1" colspan="1">0.008</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Black race, n (%)</td>
                        <td align="left" rowspan="1" colspan="1">9692 (32.4)</td>
                        <td align="left" rowspan="1" colspan="1">372 (51.8)</td>
                        <td align="left" rowspan="1" colspan="1">8982 (31.5)</td>
                        <td align="left" rowspan="1" colspan="1">338 (49.6)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.0001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Nonblack race, n (%)</td>
                        <td align="left" rowspan="1" colspan="1">20 200 (67.6)</td>
                        <td align="left" rowspan="1" colspan="1">346 (48.2)</td>
                        <td align="left" rowspan="1" colspan="1">19 511 (68.5)</td>
                        <td align="left" rowspan="1" colspan="1">343 (50.4)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.0001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Men, n (%)</td>
                        <td align="left" rowspan="1" colspan="1">16 819 (56.3)</td>
                        <td align="left" rowspan="1" colspan="1">439 (61.1)</td>
                        <td align="left" rowspan="1" colspan="1">16 028 (56.3)</td>
                        <td align="left" rowspan="1" colspan="1">352 (51.7)</td>
                        <td align="left" rowspan="1" colspan="1">0.002</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">HTN treated &gt;2 mo, n (%)</td>
                        <td align="left" rowspan="1" colspan="1">26 122 (87.4)</td>
                        <td align="left" rowspan="1" colspan="1">582 (81.1)</td>
                        <td align="left" rowspan="1" colspan="1">24 923 (87.5)</td>
                        <td align="left" rowspan="1" colspan="1">617 (90.6)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.0001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">BMI (SD), kg/m<sup>2</sup>
</td>
                        <td align="left" rowspan="1" colspan="1">29.7 (5.8)</td>
                        <td align="left" rowspan="1" colspan="1">27.8 (5.2)</td>
                        <td align="left" rowspan="1" colspan="1">29.7 (5.8)</td>
                        <td align="left" rowspan="1" colspan="1">28.3 (5.5)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.0001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Baseline SBP (SD), mm Hg</td>
                        <td align="left" rowspan="1" colspan="1">145.8 (15.6)</td>
                        <td align="left" rowspan="1" colspan="1">151.2 (15.5)</td>
                        <td align="left" rowspan="1" colspan="1">145.6 (15.6)</td>
                        <td align="left" rowspan="1" colspan="1">146.8 (15.5)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.0001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Baseline DBP (SD), mm Hg</td>
                        <td align="left" rowspan="1" colspan="1">83.8 (10.0)</td>
                        <td align="left" rowspan="1" colspan="1">85.6 (10.3)</td>
                        <td align="left" rowspan="1" colspan="1">83.7 (10.0)</td>
                        <td align="left" rowspan="1" colspan="1">83.4 (10.8)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.0001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Hx of MI/stroke, n (%)</td>
                        <td align="left" rowspan="1" colspan="1">6915 (23.1)</td>
                        <td align="left" rowspan="1" colspan="1">141 (19.6)</td>
                        <td align="left" rowspan="1" colspan="1">6636 (23.3)</td>
                        <td align="left" rowspan="1" colspan="1">138 (20.3)</td>
                        <td align="left" rowspan="1" colspan="1">0.014</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Hx of revascularization, n (%)</td>
                        <td align="left" rowspan="1" colspan="1">4192 (14.0)</td>
                        <td align="left" rowspan="1" colspan="1">80 (11.1)</td>
                        <td align="left" rowspan="1" colspan="1">4052 (14.2)</td>
                        <td align="left" rowspan="1" colspan="1">60 (8.8)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.0001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Hx of ST‐T, n (%)</td>
                        <td align="left" rowspan="1" colspan="1">3090 (10.3)</td>
                        <td align="left" rowspan="1" colspan="1">81 (11.3)</td>
                        <td align="left" rowspan="1" colspan="1">2931 (10.3)</td>
                        <td align="left" rowspan="1" colspan="1">78 (11.5)</td>
                        <td align="left" rowspan="1" colspan="1">0.431</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Hx of other CVD, n (%)</td>
                        <td align="left" rowspan="1" colspan="1">7288 (24.4)</td>
                        <td align="left" rowspan="1" colspan="1">132 (18.4)</td>
                        <td align="left" rowspan="1" colspan="1">6987 (24.5)</td>
                        <td align="left" rowspan="1" colspan="1">169 (24.8)</td>
                        <td align="left" rowspan="1" colspan="1">0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Hx of CHD, n (%)</td>
                        <td align="left" rowspan="1" colspan="1">7854 (26.3)</td>
                        <td align="left" rowspan="1" colspan="1">170 (23.7)</td>
                        <td align="left" rowspan="1" colspan="1">7535 (26.5)</td>
                        <td align="left" rowspan="1" colspan="1">149 (21.9)</td>
                        <td align="left" rowspan="1" colspan="1">0.008</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Diabetes mellitus, n (%)</td>
                        <td align="left" rowspan="1" colspan="1">10 249 (34.3)</td>
                        <td align="left" rowspan="1" colspan="1">176 (24.5)</td>
                        <td align="left" rowspan="1" colspan="1">9853 (34.6)</td>
                        <td align="left" rowspan="1" colspan="1">220 (32.3)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.0001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">HDL &lt;35 mg/dL, n (%)</td>
                        <td align="left" rowspan="1" colspan="1">3781 (12.7)</td>
                        <td align="left" rowspan="1" colspan="1">48 (6.7)</td>
                        <td align="left" rowspan="1" colspan="1">3665 (12.9)</td>
                        <td align="left" rowspan="1" colspan="1">68 (10.0)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.0001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Smoking, n (%)</td>
                        <td align="left" rowspan="1" colspan="1">6363 (21.3)</td>
                        <td align="left" rowspan="1" colspan="1">197 (27.4)</td>
                        <td align="left" rowspan="1" colspan="1">5990 (21.0)</td>
                        <td align="left" rowspan="1" colspan="1">176 (25.8)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.0001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Baseline ECG LVH, n (%)</td>
                        <td align="left" rowspan="1" colspan="1">4857 (16.3)</td>
                        <td align="left" rowspan="1" colspan="1">395 (55.0)</td>
                        <td align="left" rowspan="1" colspan="1">4291 (15.1)</td>
                        <td align="left" rowspan="1" colspan="1">171 (25.1)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.0001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Baseline echo‐LVH, n (%)</td>
                        <td align="left" rowspan="1" colspan="1">1450 (4.9)</td>
                        <td align="left" rowspan="1" colspan="1">31 (4.3)</td>
                        <td align="left" rowspan="1" colspan="1">1387 (4.9)</td>
                        <td align="left" rowspan="1" colspan="1">32 (4.7)</td>
                        <td align="left" rowspan="1" colspan="1">0.781</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">LL trial, n (%)</td>
                        <td align="left" rowspan="1" colspan="1">8206 (27.5)</td>
                        <td align="left" rowspan="1" colspan="1">197 (27.4)</td>
                        <td align="left" rowspan="1" colspan="1">7825 (27.5)</td>
                        <td align="left" rowspan="1" colspan="1">184 (27.0)</td>
                        <td align="left" rowspan="1" colspan="1">0.968</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Doxazosin ITT, n (%)</td>
                        <td align="left" rowspan="1" colspan="1">5967 (20)</td>
                        <td align="left" rowspan="1" colspan="1">122 (2.0)</td>
                        <td align="left" rowspan="1" colspan="1">5698 (95.5)</td>
                        <td align="left" rowspan="1" colspan="1">147 (2.5)</td>
                        <td align="left" rowspan="1" colspan="1">0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Chlorthalidone ITT, n (%)</td>
                        <td align="left" rowspan="1" colspan="1">11 008 (37)</td>
                        <td align="left" rowspan="1" colspan="1">262 (2.4)</td>
                        <td align="left" rowspan="1" colspan="1">10 516 (95.5)</td>
                        <td align="left" rowspan="1" colspan="1">230 (2.1)</td>
                        <td align="left" rowspan="1" colspan="1">0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Amlodipine ITT, n (%)</td>
                        <td align="left" rowspan="1" colspan="1">6593 (22)</td>
                        <td align="left" rowspan="1" colspan="1">193 (2.9)</td>
                        <td align="left" rowspan="1" colspan="1">6270 (95.1)</td>
                        <td align="left" rowspan="1" colspan="1">130 (2.00)</td>
                        <td align="left" rowspan="1" colspan="1">0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Lisinopril ITT, n (%)</td>
                        <td align="left" rowspan="1" colspan="1">6324 (21)</td>
                        <td align="left" rowspan="1" colspan="1">141 (2.4)</td>
                        <td align="left" rowspan="1" colspan="1">6009 (95.0)</td>
                        <td align="left" rowspan="1" colspan="1">174 (2.8)</td>
                        <td align="left" rowspan="1" colspan="1">0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">SBP change (SD), mm Hg</td>
                        <td align="left" rowspan="1" colspan="1">−10.9 (20.0)</td>
                        <td align="left" rowspan="1" colspan="1">−16.2 (21.3)</td>
                        <td align="left" rowspan="1" colspan="1">−10.6 (19.9)</td>
                        <td align="left" rowspan="1" colspan="1">−6.2 (22.3)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.0001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">DBP change (SD), mm Hg</td>
                        <td align="left" rowspan="1" colspan="1">−7.3 (11.7)</td>
                        <td align="left" rowspan="1" colspan="1">−9.9 (12.2)</td>
                        <td align="left" rowspan="1" colspan="1">−7.3 (11.7)</td>
                        <td align="left" rowspan="1" colspan="1">−5.5 (12.5)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.0001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Incident HF, n (%)</td>
                        <td align="left" rowspan="1" colspan="1">2049 (6.9)</td>
                        <td align="left" rowspan="1" colspan="1">65 (9.1)</td>
                        <td align="left" rowspan="1" colspan="1">1901 (6.7)</td>
                        <td align="left" rowspan="1" colspan="1">83 (12.2)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.0001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Hospitalized/fatal HF, n (%)</td>
                        <td align="left" rowspan="1" colspan="1">1598 (5.4)</td>
                        <td align="left" rowspan="1" colspan="1">53 (7.4)</td>
                        <td align="left" rowspan="1" colspan="1">1478 (5.2)</td>
                        <td align="left" rowspan="1" colspan="1">67 (9.8)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.0001</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn id="jah33961-note-0001">
                      <p>BMI indicates body mass index; CHD, coronary heart disease; CVD, cardiovascular disease; DBP, diastolic blood pressure; HDL, high‐density lipoprotein; HF, heart failure; HTN, hypertension; Hx, history; ITT, intention‐to‐treat; LL, lipid‐lowering; LVH, left ventricular hypertrophy; MI, myocardial infarction; SBP, systolic blood pressure; ST‐T, major ST depression or T‐wave inversion on ECG.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="jah33961-sec-0020">
                <title>Serial ECG Changes: Evolving ECG LVH</title>
                <p>Overall, 58 366 serial ECG changes were evaluated. ECG LVH resolution was observed in about 2% of participants, and ECG LVH progression in another 2% (Table <xref rid="jah33961-tbl-0001" ref-type="table">1</xref>). The majority of participants had no evolving ECG LVH changes. ALLHAT participants with evolving ECG LVH were more likely black males, current smokers, with lower BMI but less likely to have CHD/MI history. As expected, baseline ECG LVH was more frequent in participants with resolving ECG LVH. Baseline LVH by ECG was similar in all 3 groups and was very infrequent (4% to 5%). Participants with resolving LVH by ECG were more likely diabetic, less likely to have been treated for HTN before the onset of the trial, and achieved the greatest degree of BP lowering in the trial. Incident HF was significantly more frequent in participants with evolving ECG LVH (Table <xref rid="jah33961-tbl-0001" ref-type="table">1</xref>). Doxazosin and lisinopril intention to treat was more likely to be associated with progressing ECG LVH and less likely associated with ECG LVH reduction. In contrast, chlorthalidone and amlodipine intention to treat was more likely to be associated with ECG LVH reduction and less likely associated with ECG LVH progression (Table <xref rid="jah33961-tbl-0001" ref-type="table">1</xref>).</p>
              </sec>
              <sec id="jah33961-sec-0021">
                <title>Dynamic Changes in Blood Pressure in Trial</title>
                <p>The first (Q1), second (Q2), and third (Q3) tertiles of the greatest BP lowering were −32/−19±10/6, −11/−7±5/3, and +11/6±12/7 mm Hg, respectively. Q1, Q2, and Q3 of the fastest BP lowering were −28/−16±10/6, −7/−4±5/3, and +14/8±12/6 mm Hg, accordingly. Hispanic ethnicity, previously untreated HTN, higher baseline levels of SBP/DBP (Figure <xref rid="jah33961-fig-0003" ref-type="fig">3</xref>) and baseline ECG LVH were associated with greater SBP and DBP lowering in trial (Table <xref rid="jah33961-tbl-0002" ref-type="table">2</xref>). In contrast, the presence of diabetes mellitus was associated with a SBP increase of nearly 2 mm Hg. Older age was associated with greater SBP lowering but slight DBP increase. A history of CHD/cardiovascular disease did not affect the degree of BP lowering in trial. Compared with chlorthalidone, doxazosin was associated with a significant SBP increase (by nearly 2 mm Hg), whereas amlodipine was associated with significant SBP and DBP decreases. Lisinopril was associated with greater DBP (but not SBP) lowering than chlorthalidone (Table <xref rid="jah33961-tbl-0002" ref-type="table">2</xref>). Participants in the doxazosin arm who developed HF had the greatest degree of BP lowering (both SBP/DBP) in trial (≈6/2 mm Hg lower than by diuretic), which contrasted with the overall weak BP‐lowering effect of doxazosin in the trial (Table <xref rid="jah33961-tbl-0002" ref-type="table">2</xref>).</p>
                <fig fig-type="Figure" xml:lang="en" id="jah33961-fig-0003" orientation="portrait" position="float">
                  <label>Figure 3</label>
                  <caption>
                    <p>Scatterplots of (<bold>A</bold>) in‐trial systolic blood pressure (<styled-content style="fixed-case">SBP</styled-content>) change (Y‐axis) against baseline <styled-content style="fixed-case">SBP</styled-content> (X‐axis), and (<bold>B</bold>) diastolic blood pressure (<styled-content style="fixed-case">DBP</styled-content>) change (Y‐axis) against baseline <styled-content style="fixed-case">DBP</styled-content> (X‐axis). A line of the best linear fit is shown.</p>
                  </caption>
                  <graphic id="nlm-graphic-5" xlink:href="JAH3-8-e011961-g003"/>
                </fig>
                <table-wrap id="jah33961-tbl-0002" xml:lang="en" orientation="portrait" position="float">
                  <label>Table 2</label>
                  <caption>
                    <p>Associations of Clinical Characteristics With BP Change in Trial in Linear Regression Models</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <thead valign="top">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="top" rowspan="1" colspan="1">Characteristic</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">Systolic BP Change (95% CI), mm Hg</th>
                        <th align="left" valign="top" rowspan="1" colspan="1"><italic>P</italic> Value</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">Diastolic BP Change (95% CI), mm Hg</th>
                        <th align="left" valign="top" rowspan="1" colspan="1"><italic>P</italic> Value</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Age, per 1 y increase</td>
                        <td align="left" rowspan="1" colspan="1">−0.13 (−0.16 to −0.10)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.0001<xref ref-type="fn" rid="jah33961-note-0003">a</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">+0.02 (0.006‐0.04)</td>
                        <td align="left" rowspan="1" colspan="1">0.009<xref ref-type="fn" rid="jah33961-note-0003">a</xref>
</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="5" rowspan="1">Race/ethnicity</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">White non‐Hispanic</td>
                        <td align="left" rowspan="1" colspan="1">Reference</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">Reference</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Black non‐Hispanic</td>
                        <td align="left" rowspan="1" colspan="1">+3.09 (2.57‐3.61)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.0001<xref ref-type="fn" rid="jah33961-note-0003">a</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">+1.59 (1.29‐1.90)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.0001<xref ref-type="fn" rid="jah33961-note-0003">a</xref>
</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">White Hispanic</td>
                        <td align="left" rowspan="1" colspan="1">−3.64 (−4.42 to −2.86)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.0001<xref ref-type="fn" rid="jah33961-note-0003">a</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">−1.32 (−1.78 to −0.87)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.0001<xref ref-type="fn" rid="jah33961-note-0003">a</xref>
</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Black Hispanic</td>
                        <td align="left" rowspan="1" colspan="1">−3.79 (−5.37 to −1.19)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.0001<xref ref-type="fn" rid="jah33961-note-0003">a</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">−0.89 (−1.82 to 0.03)</td>
                        <td align="left" rowspan="1" colspan="1">0.076</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Women</td>
                        <td align="left" rowspan="1" colspan="1">+0.44 (−0.02 to 0.90)</td>
                        <td align="left" rowspan="1" colspan="1">0.063</td>
                        <td align="left" rowspan="1" colspan="1">+0.67 (0.40‐0.94)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.0001<xref ref-type="fn" rid="jah33961-note-0003">a</xref>
</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="5" rowspan="1">HTN treated</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">≥2 months</td>
                        <td align="left" rowspan="1" colspan="1">Reference</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">Reference</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">&lt;2 months</td>
                        <td align="left" rowspan="1" colspan="1">−6.89 (−8.16 to −5.61)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.0001<xref ref-type="fn" rid="jah33961-note-0003">a</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">−3.70 (−4.45 to −2.94)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.0001<xref ref-type="fn" rid="jah33961-note-0003">a</xref>
</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Not treated</td>
                        <td align="left" rowspan="1" colspan="1">−11.85 (−12.61 to −11.08)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.0001<xref ref-type="fn" rid="jah33961-note-0003">a</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">−5.74 (−6.19 to −5.29)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.0001<xref ref-type="fn" rid="jah33961-note-0003">a</xref>
</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">BMI, per 1 kg/m<sup>2</sup> increase</td>
                        <td align="left" rowspan="1" colspan="1">+0.04 (−0.0008 to 0.08)</td>
                        <td align="left" rowspan="1" colspan="1">0.055</td>
                        <td align="left" rowspan="1" colspan="1">−0.004 (−0.03 to 0.02)</td>
                        <td align="left" rowspan="1" colspan="1">0.701</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Baseline SBP, per 1 mm Hg increase</td>
                        <td align="left" rowspan="1" colspan="1">−0.78 (−0.80 to −0.77)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.0001<xref ref-type="fn" rid="jah33961-note-0003">a</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">−0.29 (−0.29 to −0.28)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.0001<xref ref-type="fn" rid="jah33961-note-0003">a</xref>
</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Baseline DBP, per 1 mm Hg increase</td>
                        <td align="left" rowspan="1" colspan="1">−0.71 (−0.73 to −0.69)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.0001<xref ref-type="fn" rid="jah33961-note-0003">a</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">−0.72 (−0.73 to −0.71)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.0001<xref ref-type="fn" rid="jah33961-note-0003">a</xref>
</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Hx of MI/stroke</td>
                        <td align="left" rowspan="1" colspan="1">−0.22 (−0.77 to 0.32)</td>
                        <td align="left" rowspan="1" colspan="1">0.423</td>
                        <td align="left" rowspan="1" colspan="1">+0.22 (−0.10 to 0.54)</td>
                        <td align="left" rowspan="1" colspan="1">0.178</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Hx of revascularization</td>
                        <td align="left" rowspan="1" colspan="1">+0.07 (−0.60 to 0.74)</td>
                        <td align="left" rowspan="1" colspan="1">0.843</td>
                        <td align="left" rowspan="1" colspan="1">+0.08 (−0.31 to 0.47)</td>
                        <td align="left" rowspan="1" colspan="1">0.692</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Hx of ST‐T on ECG</td>
                        <td align="left" rowspan="1" colspan="1">−0.49 (−1.24 to 0.25)</td>
                        <td align="left" rowspan="1" colspan="1">0.194</td>
                        <td align="left" rowspan="1" colspan="1">−0.12 (−0.56 to 0.32)</td>
                        <td align="left" rowspan="1" colspan="1">0.592</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Hx of other CVD</td>
                        <td align="left" rowspan="1" colspan="1">−0.32 (−0.85 to 0.22)</td>
                        <td align="left" rowspan="1" colspan="1">0.245</td>
                        <td align="left" rowspan="1" colspan="1">+0.30 (−0.01 to 0.61)</td>
                        <td align="left" rowspan="1" colspan="1">0.061</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Hx of CHD</td>
                        <td align="left" rowspan="1" colspan="1">−0.62 (−1.15 to −0.09)</td>
                        <td align="left" rowspan="1" colspan="1">0.022<xref ref-type="fn" rid="jah33961-note-0003">a</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">+0.03 (−0.28 to 0.34)</td>
                        <td align="left" rowspan="1" colspan="1">0.827</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Diabetes mellitus</td>
                        <td align="left" rowspan="1" colspan="1">+1.64 (1.17‐2.11)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.0001<xref ref-type="fn" rid="jah33961-note-0003">a</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">+0.20 (−0.08 to 0.48)</td>
                        <td align="left" rowspan="1" colspan="1">0.154</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">HDL &lt;35 mg/dL</td>
                        <td align="left" rowspan="1" colspan="1">+0.86 (0.17‐1.55)</td>
                        <td align="left" rowspan="1" colspan="1">0.014<xref ref-type="fn" rid="jah33961-note-0003">a</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">+0.30 (−0.11 to 0.70)</td>
                        <td align="left" rowspan="1" colspan="1">0.152</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="5" rowspan="1">Smoking</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Never</td>
                        <td align="left" rowspan="1" colspan="1">Reference</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">Reference</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Past</td>
                        <td align="left" rowspan="1" colspan="1">−0.12 (−0.66 to 0.43)</td>
                        <td align="left" rowspan="1" colspan="1">0.675</td>
                        <td align="left" rowspan="1" colspan="1">−0.15 (−0.84 to 0.16)</td>
                        <td align="left" rowspan="1" colspan="1">0.334</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Current</td>
                        <td align="left" rowspan="1" colspan="1">−1.13 (−1.77 to −0.49)</td>
                        <td align="left" rowspan="1" colspan="1">0.001<xref ref-type="fn" rid="jah33961-note-0003">a</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">−0.46 (−0.84 to −0.09)</td>
                        <td align="left" rowspan="1" colspan="1">0.016<xref ref-type="fn" rid="jah33961-note-0003">a</xref>
</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Baseline ECG LVH</td>
                        <td align="left" rowspan="1" colspan="1">−1.58 (−2.20 to −0.95)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.0001<xref ref-type="fn" rid="jah33961-note-0003">a</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">−0.95 (−1.31 to −0.58)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.0001<xref ref-type="fn" rid="jah33961-note-0003">a</xref>
</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Baseline echo LVH</td>
                        <td align="left" rowspan="1" colspan="1">−0.97 (−2.02 to 0.08)</td>
                        <td align="left" rowspan="1" colspan="1">0.071</td>
                        <td align="left" rowspan="1" colspan="1">+0.53 (−0.08 to 1.15)</td>
                        <td align="left" rowspan="1" colspan="1">0.091</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="5" rowspan="1">Treatment arm</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Chlorthalidone ITT</td>
                        <td align="left" rowspan="1" colspan="1">Reference</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">Reference</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Doxazosin ITT</td>
                        <td align="left" rowspan="1" colspan="1">+1.68 (1.05‐2.30)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.0001<xref ref-type="fn" rid="jah33961-note-0003">a</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">−0.29 (−0.66 to 0.08)</td>
                        <td align="left" rowspan="1" colspan="1">0.124</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Amlodipine ITT</td>
                        <td align="left" rowspan="1" colspan="1">−1.25 (−1.86 to −0.65)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.0001<xref ref-type="fn" rid="jah33961-note-0003">a</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">−2.09 (−2.44 to −1.73)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.0001<xref ref-type="fn" rid="jah33961-note-0003">a</xref>
</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Lisinopril ITT</td>
                        <td align="left" rowspan="1" colspan="1">−0.16 (−0.77 to 0.46)</td>
                        <td align="left" rowspan="1" colspan="1">0.616</td>
                        <td align="left" rowspan="1" colspan="1">−1.37 (−1.73 to −1.01)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.0001<xref ref-type="fn" rid="jah33961-note-0003">a</xref>
</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Incident HF</td>
                        <td align="left" rowspan="1" colspan="1">−2.66 (−3.56 to −1.76)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.0001<xref ref-type="fn" rid="jah33961-note-0003">a</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">−1.23 (−1.76 to −0.70)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.0001<xref ref-type="fn" rid="jah33961-note-0003">a</xref>
</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Incident HF ## doxazosin</td>
                        <td align="left" rowspan="1" colspan="1">−5.33 (−7.86 to −2.80)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.0001<xref ref-type="fn" rid="jah33961-note-0003">a</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">−1.88 (−3.36 to −0.40)</td>
                        <td align="left" rowspan="1" colspan="1">0.013<xref ref-type="fn" rid="jah33961-note-0003">a</xref>
</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Hospitalized/fatal HF</td>
                        <td align="left" rowspan="1" colspan="1">−2.56 (−3.57 to −1.55)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.0001<xref ref-type="fn" rid="jah33961-note-0003">a</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">−1.22 (−1.81 to −0.62)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.0001<xref ref-type="fn" rid="jah33961-note-0003">a</xref>
</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Hospitalized/fatal HF ## doxazosin</td>
                        <td align="left" rowspan="1" colspan="1">−5.97 (−8.85 to −3.09)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.0001<xref ref-type="fn" rid="jah33961-note-0003">a</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">−2.06 (−3.74 to 0.37)</td>
                        <td align="left" rowspan="1" colspan="1">0.017<xref ref-type="fn" rid="jah33961-note-0003">a</xref>
</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn id="jah33961-note-0002">
                      <p>BMI indicates body mass index; BP, blood pressure; CHD, coronary heart disease; CVD, cardiovascular disease; DBP, diastolic BP; HDL, high density lipoprotein; HF, heart failure; HTN, hypertension; Hx, history; ITT, intention‐to‐treat; LVH, left ventricular hypertrophy; MI, myocardial infarction; SBP, systolic BP; ST‐T, major ST depression or T‐wave inversion on ECG. ## Significant interaction with treatment group. Participants in the doxazosin arm who developed HF or hospitalized/fatal HF</p>
                    </fn>
                    <fn id="jah33961-note-0003">
                      <label>a</label>
                      <p><italic>P</italic>&lt;0.05.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="jah33961-sec-0022">
                <title>Risk Factors for Heart Failure</title>
                <p>As expected, age, ethnicity, history of HTN, CHD, and cardiovascular disease as well as ECG LVH were associated with increased risk of HF (Table <xref rid="jah33961-tbl-0003" ref-type="table">3</xref>). There were very small differences between risk factors of 2 incident HF outcomes: incident symptomatic HF and hospitalized/fatal HF.</p>
                <table-wrap id="jah33961-tbl-0003" xml:lang="en" orientation="portrait" position="float">
                  <label>Table 3</label>
                  <caption>
                    <p>Associations of Clinical Characteristics With Incident Heart Failure in Cox Regression Models</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <thead valign="top">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="top" rowspan="1" colspan="1">Characteristic</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">Incident Symptomatic HF HR (95% CI)</th>
                        <th align="left" valign="top" rowspan="1" colspan="1"><italic>P</italic> Value</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">Hospitalized/Fatal HF HR (95% CI)</th>
                        <th align="left" valign="top" rowspan="1" colspan="1"><italic>P</italic> Value</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Age, per 1 y increase</td>
                        <td align="left" rowspan="1" colspan="1">1.06 (1.05‐1.06)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.0001<xref ref-type="fn" rid="jah33961-note-0005">a</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">1.06 (1.05‐1.07)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.0001<xref ref-type="fn" rid="jah33961-note-0005">a</xref>
</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="5" rowspan="1">Race/ethnicity</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">White non‐Hispanic</td>
                        <td align="left" rowspan="1" colspan="1">Reference</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">Reference</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Black non‐Hispanic</td>
                        <td align="left" rowspan="1" colspan="1">0.94 (0.86‐1.04)</td>
                        <td align="left" rowspan="1" colspan="1">0.234</td>
                        <td align="left" rowspan="1" colspan="1">0.97 (0.87‐1.09)</td>
                        <td align="left" rowspan="1" colspan="1">0.634</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">White Hispanic</td>
                        <td align="left" rowspan="1" colspan="1">0.41 (0.32‐0.51)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.0001<xref ref-type="fn" rid="jah33961-note-0005">a</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">0.47 (0.37‐0.60)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.0001<xref ref-type="fn" rid="jah33961-note-0005">a</xref>
</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Black Hispanic</td>
                        <td align="left" rowspan="1" colspan="1">0.50 (0.33‐0.77)</td>
                        <td align="left" rowspan="1" colspan="1">0.002<xref ref-type="fn" rid="jah33961-note-0005">a</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">0.54 (0.34‐0.88)</td>
                        <td align="left" rowspan="1" colspan="1">0.013<xref ref-type="fn" rid="jah33961-note-0005">a</xref>
</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Women</td>
                        <td align="left" rowspan="1" colspan="1">0.91 (0.84‐0.999)</td>
                        <td align="left" rowspan="1" colspan="1">0.048<xref ref-type="fn" rid="jah33961-note-0005">a</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">0.93 (0.84‐1.03)</td>
                        <td align="left" rowspan="1" colspan="1">0.177</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="5" rowspan="1">HTN treated</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">≥2 months</td>
                        <td align="left" rowspan="1" colspan="1">Reference</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">Reference</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">&lt;2 months</td>
                        <td align="left" rowspan="1" colspan="1">1.04 (0.81‐1.34)</td>
                        <td align="left" rowspan="1" colspan="1">0.732</td>
                        <td align="left" rowspan="1" colspan="1">1.21 (0.93‐1.58)</td>
                        <td align="left" rowspan="1" colspan="1">0.148</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Not treated</td>
                        <td align="left" rowspan="1" colspan="1">0.68 (0.57‐0.81)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.0001<xref ref-type="fn" rid="jah33961-note-0005">a</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">0.71 (0.58‐0.87)</td>
                        <td align="left" rowspan="1" colspan="1">0.001<xref ref-type="fn" rid="jah33961-note-0005">a</xref>
</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">BMI, per 1 kg/m<sup>2</sup> increase</td>
                        <td align="left" rowspan="1" colspan="1">1.05 (1.04‐1.05)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.0001<xref ref-type="fn" rid="jah33961-note-0005">a</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">1.04 (1.03‐1.05)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.0001<xref ref-type="fn" rid="jah33961-note-0005">a</xref>
</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Baseline SBP, per 1 mm Hg increase</td>
                        <td align="left" rowspan="1" colspan="1">1.006 (1.004‐1.009)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.0001<xref ref-type="fn" rid="jah33961-note-0005">a</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">1.009 (1.006‐1.01)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.0001<xref ref-type="fn" rid="jah33961-note-0005">a</xref>
</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Baseline DBP, per 1 mm Hg increase</td>
                        <td align="left" rowspan="1" colspan="1">0.990 (0.986‐0.995)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.0001<xref ref-type="fn" rid="jah33961-note-0005">a</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">0.990 (0.985‐0.995)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.0001<xref ref-type="fn" rid="jah33961-note-0005">a</xref>
</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Hx of MI/stroke</td>
                        <td align="left" rowspan="1" colspan="1">1.75 (1.59‐1.91)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.0001<xref ref-type="fn" rid="jah33961-note-0005">a</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">1.78 (1.61‐1.98)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.0001<xref ref-type="fn" rid="jah33961-note-0005">a</xref>
</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Hx of revascularization</td>
                        <td align="left" rowspan="1" colspan="1">1.73 (1.55‐1.92)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.0001<xref ref-type="fn" rid="jah33961-note-0005">a</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">1.65 (1.46‐1.87)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.0001<xref ref-type="fn" rid="jah33961-note-0005">a</xref>
</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Hx of ST‐T on ECG</td>
                        <td align="left" rowspan="1" colspan="1">1.10 (0.96‐1.26)</td>
                        <td align="left" rowspan="1" colspan="1">0.159</td>
                        <td align="left" rowspan="1" colspan="1">1.14 (0.98‐1.33)</td>
                        <td align="left" rowspan="1" colspan="1">0.080</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Hx of other CVD</td>
                        <td align="left" rowspan="1" colspan="1">1.26 (1.15‐1.39)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.0001<xref ref-type="fn" rid="jah33961-note-0005">a</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">1.27 (1.14‐1.41)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.0001<xref ref-type="fn" rid="jah33961-note-0005">a</xref>
</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Hx of CHD</td>
                        <td align="left" rowspan="1" colspan="1">1.66 (1.52‐1.82)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.0001<xref ref-type="fn" rid="jah33961-note-0005">a</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">1.62 (1.46‐1.80)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.0001<xref ref-type="fn" rid="jah33961-note-0005">a</xref>
</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Diabetes mellitus</td>
                        <td align="left" rowspan="1" colspan="1">1.71 (1.57‐1.87)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.0001<xref ref-type="fn" rid="jah33961-note-0005">a</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">1.85 (1.67‐2.04)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.0001<xref ref-type="fn" rid="jah33961-note-0005">a</xref>
</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">HDL &lt;35 mg/dL</td>
                        <td align="left" rowspan="1" colspan="1">0.98 (0.86‐1.11)</td>
                        <td align="left" rowspan="1" colspan="1">0.731</td>
                        <td align="left" rowspan="1" colspan="1">0.97 (0.84‐1.13)</td>
                        <td align="left" rowspan="1" colspan="1">0.718</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="5" rowspan="1">Smoking</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Never</td>
                        <td align="left" rowspan="1" colspan="1">Reference</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">Reference</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Past</td>
                        <td align="left" rowspan="1" colspan="1">1.19 (1.08‐1.32)</td>
                        <td align="left" rowspan="1" colspan="1">0.001<xref ref-type="fn" rid="jah33961-note-0005">a</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">1.21 (1.08‐1.36)</td>
                        <td align="left" rowspan="1" colspan="1">0.001<xref ref-type="fn" rid="jah33961-note-0005">a</xref>
</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Current</td>
                        <td align="left" rowspan="1" colspan="1">1.07 (0.94‐1.23)</td>
                        <td align="left" rowspan="1" colspan="1">0.312</td>
                        <td align="left" rowspan="1" colspan="1">1.17 (1.01‐1.36)</td>
                        <td align="left" rowspan="1" colspan="1">0.036<xref ref-type="fn" rid="jah33961-note-0005">a</xref>
</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Baseline ECG LVH</td>
                        <td align="left" rowspan="1" colspan="1">1.17 (1.04‐1.31)</td>
                        <td align="left" rowspan="1" colspan="1">0.008<xref ref-type="fn" rid="jah33961-note-0005">a</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">1.16 (1.02‐1.32)</td>
                        <td align="left" rowspan="1" colspan="1">0.023<xref ref-type="fn" rid="jah33961-note-0005">a</xref>
</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Baseline echo LVH</td>
                        <td align="left" rowspan="1" colspan="1">1.00 (0.92‐1.21)</td>
                        <td align="left" rowspan="1" colspan="1">0.972</td>
                        <td align="left" rowspan="1" colspan="1">1.06 (0.86‐1.32)</td>
                        <td align="left" rowspan="1" colspan="1">0.576</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="5" rowspan="1">Evolving ECG LVH</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Absent</td>
                        <td align="left" rowspan="1" colspan="1">Reference</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">Reference</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Resolving</td>
                        <td align="left" rowspan="1" colspan="1">1.33 (1.03‐1.70)</td>
                        <td align="left" rowspan="1" colspan="1">0.026<xref ref-type="fn" rid="jah33961-note-0005">a</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">1.39 (1.05‐1.83)</td>
                        <td align="left" rowspan="1" colspan="1">0.020<xref ref-type="fn" rid="jah33961-note-0005">a</xref>
</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Progressing</td>
                        <td align="left" rowspan="1" colspan="1">1.78 (1.43‐2.22)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.0001<xref ref-type="fn" rid="jah33961-note-0005">a</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">1.84 (1.44‐2.35)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.0001<xref ref-type="fn" rid="jah33961-note-0005">a</xref>
</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">SBP lowering by 3 to 19 mm Hg (Q2): Reference</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">&lt;0.0001<xref ref-type="fn" rid="jah33961-note-0005">a</xref>
</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">By 20 mm Hg or more (Q1)</td>
                        <td align="left" rowspan="1" colspan="1">1.34 (1.20‐1.49)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.0001<xref ref-type="fn" rid="jah33961-note-0005">a</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">1.41 (1.25‐1.60)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.0001<xref ref-type="fn" rid="jah33961-note-0005">a</xref>
</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">By 2 mm Hg or less (Q3)</td>
                        <td align="left" rowspan="1" colspan="1">1.08 (0.97‐1.21)</td>
                        <td align="left" rowspan="1" colspan="1">0.154</td>
                        <td align="left" rowspan="1" colspan="1">1.14 (1.01‐1.30)</td>
                        <td align="left" rowspan="1" colspan="1">0.039<xref ref-type="fn" rid="jah33961-note-0005">a</xref>
</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="5" rowspan="1">DBP lowering by 2 to 11 mm Hg (Q2): Reference</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">By 12 mm Hg or more (Q1)</td>
                        <td align="left" rowspan="1" colspan="1">1.31 (1.18‐1.45)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.0001<xref ref-type="fn" rid="jah33961-note-0005">a</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">1.32 (1.17‐1.49)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.0001<xref ref-type="fn" rid="jah33961-note-0005">a</xref>
</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">By 1 mm Hg or less (Q3)</td>
                        <td align="left" rowspan="1" colspan="1">1.09 (0.97‐1.21)</td>
                        <td align="left" rowspan="1" colspan="1">0.155</td>
                        <td align="left" rowspan="1" colspan="1">1.12 (0.98‐1.27)</td>
                        <td align="left" rowspan="1" colspan="1">0.088</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn id="jah33961-note-0004">
                      <p>BMI indicates body mass index; CHD, coronary heart disease; CVD, cardiovascular disease; DBP, diastolic blood pressure; HDL, high‐density lipoprotein; HF, heart failure; HR, hazard ratio; HTN, hypertension; Hx, history; LVH, left ventricular hypertrophy; MI, myocardial infarction; Q1/Q2/Q3, first/second/third tertile; SBP, systolic blood pressure; ST‐T, major ST depression or T‐wave inversion on ECG.</p>
                    </fn>
                    <fn id="jah33961-note-0005">
                      <label>a</label>
                      <p><italic>P</italic>&lt;0.05.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <p>Evolving ECG LVH was associated with incident HF (Figure <xref rid="jah33961-fig-0004" ref-type="fig">4</xref>), although progressing ECG LVH carried a larger risk, as compared with resolving ECG LVH. Evolving LVH was associated with incident HF in 3 out of 4 treatment groups (<italic>P</italic>
<sub>interaction</sub>=0.056; Figure <xref rid="jah33961-fig-0005" ref-type="fig">5</xref>).</p>
                <fig fig-type="Figure" xml:lang="en" id="jah33961-fig-0004" orientation="portrait" position="float">
                  <label>Figure 4</label>
                  <caption>
                    <p>Unadjusted Kaplan‐Meier curves for probability of (<bold>A</bold>) incident symptomatic heart failure (<styled-content style="fixed-case">HF</styled-content>) and (<bold>B</bold>) hospitalized or fatal <styled-content style="fixed-case">HF</styled-content> in all treatment groups <styled-content style="fixed-case">ALLHAT</styled-content> (Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial) participants with evolving <styled-content style="fixed-case">ECG</styled-content> left ventricular hypertrophy (<styled-content style="fixed-case">LVH</styled-content>) development (blue dotted line), resolution (green dashed line), or without evolving <styled-content style="fixed-case">ECG</styled-content> changes (red solid line).</p>
                  </caption>
                  <graphic id="nlm-graphic-7" xlink:href="JAH3-8-e011961-g004"/>
                </fig>
                <fig fig-type="Figure" xml:lang="en" id="jah33961-fig-0005" orientation="portrait" position="float">
                  <label>Figure 5</label>
                  <caption>
                    <p>Unadjusted Kaplan‐Meier curves for probability of incident symptomatic heart failure (<styled-content style="fixed-case">HF</styled-content>) in (<bold>A</bold>) doxazosin, (<bold>B</bold>) chlorthalidone, (<bold>C</bold>) amlodipine, and (<bold>D</bold>) lisinopril treatment groups. Evolving <styled-content style="fixed-case">ECG</styled-content> left ventricular hypertrophy (<styled-content style="fixed-case">LVH</styled-content>) groups as described in Figure <xref rid="jah33961-fig-0003" ref-type="fig">3</xref> legend. CHF indicates congestive heart failure.</p>
                  </caption>
                  <graphic id="nlm-graphic-9" xlink:href="JAH3-8-e011961-g005"/>
                </fig>
                <p>The association of in‐trial BP changes with HF was nonlinear (Figure <xref rid="jah33961-fig-0006" ref-type="fig">6</xref>). Both a large decrease and poor control of BP were associated with incident HF, but a large decrease in BP had a stronger effect than poor BP control on both primary and secondary outcomes (Table <xref rid="jah33961-tbl-0003" ref-type="table">3</xref>). A similar association of SBP lowering with incident HF was observed in 3 out of 4 treatment groups (Figure <xref rid="jah33961-fig-0007" ref-type="fig">7</xref>). In the amlodipine treatment group, SBP change was not associated with incident HF (<italic>P</italic>
<sub>interaction</sub>=0.039; Figure <xref rid="jah33961-fig-0006" ref-type="fig">6</xref>). A noticeable U‐shaped association of DBP change with incident symptomatic HF was observed in the amlodipine and chlorthalidone treatment groups (Figure <xref rid="jah33961-fig-0007" ref-type="fig">7</xref>), whereas poor DBP control in the lisinopril and doxazosin treatment groups was not associated with incident HF.</p>
                <fig fig-type="Figure" xml:lang="en" id="jah33961-fig-0006" orientation="portrait" position="float">
                  <label>Figure 6</label>
                  <caption>
                    <p>Adjusted (by age, sex, and race/ethnicity) risk of symptomatic congestive heart failure (<styled-content style="fixed-case">HF</styled-content>) associated with achieved in‐trial greatest (<bold>A</bold>) systolic blood pressure (<styled-content style="fixed-case">SBP</styled-content>) and (<bold>B</bold>) diastolic blood pressure (<styled-content style="fixed-case">DBP</styled-content>) changes in all participants. Restricted cubic spline with 95% CI show change in hazard ratio (Y‐axis) in response to <styled-content style="fixed-case">BP</styled-content> change (X‐axis). The 50th percentile of <styled-content style="fixed-case">BP</styled-content> change is selected as the reference. <styled-content style="fixed-case">BP</styled-content> indicates blood pressure.</p>
                  </caption>
                  <graphic id="nlm-graphic-11" xlink:href="JAH3-8-e011961-g006"/>
                </fig>
                <fig fig-type="Figure" xml:lang="en" id="jah33961-fig-0007" orientation="portrait" position="float">
                  <label>Figure 7</label>
                  <caption>
                    <p>Adjusted risk of symptomatic congestive heart failure (<styled-content style="fixed-case">HF</styled-content>) associated with achieved in‐trial greatest systolic blood pressure <styled-content style="fixed-case">SBP</styled-content> (I) and diastolic blood pressure <styled-content style="fixed-case">DBP</styled-content> (<styled-content style="fixed-case">II</styled-content>) changes in (<bold>A</bold>) doxazosin, (<bold>B</bold>) chlorthalidone, (<bold>C</bold>) amlodipine, and (<bold>D</bold>) lisinopril treatment groups. See Figure <xref rid="jah33961-fig-0005" ref-type="fig">5</xref> legend for details. HR indicates hazard ratio.</p>
                  </caption>
                  <graphic id="nlm-graphic-13" xlink:href="JAH3-8-e011961-g007"/>
                </fig>
              </sec>
              <sec id="jah33961-sec-0023">
                <title>Mediation of HF Risk by Evolving LVH</title>
                <p>In fully adjusted analyses, evolving LVH mediated 4% of the effect of doxazosin on HF (Table <xref rid="jah33961-tbl-0004" ref-type="table">4</xref>). Both direct and mediated pathways contributed to the increased HF risk in the doxazosin arm. The effects of amlodipine and lisinopril on HF were entirely independent of evolving LVH.</p>
                <table-wrap id="jah33961-tbl-0004" xml:lang="en" orientation="portrait" position="float">
                  <label>Table 4</label>
                  <caption>
                    <p>Fully Adjusted Effect of Antihypertensive Treatment on Incident Symptomatic Heart Failure (Total), Through Evolving ECG LVH or BP Changes (Mediated), and Independent of BP Lowering or Evolving ECG LVH (Direct)</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <thead valign="top">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="top" rowspan="1" colspan="1">Treatment</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">Mediator</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">Controlled Direct Effect RR (95% CI)</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">Total Effect RR (95% CI)</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">Direct Effect RR (95% CI)</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">Mediated Effect RR (95% CI)</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">% Mediated</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Doxazosin</td>
                        <td align="left" rowspan="1" colspan="1">Evolving ECG LVH (reference: none)</td>
                        <td align="left" rowspan="1" colspan="1">1.16 (1.005‐1.33)</td>
                        <td align="left" rowspan="1" colspan="1">1.18 (1.03‐1.36)</td>
                        <td align="left" rowspan="1" colspan="1">1.18 (1.02‐1.36)</td>
                        <td align="left" rowspan="1" colspan="1">1.006 (1.001‐1.015)</td>
                        <td align="left" rowspan="1" colspan="1">+3.9<xref ref-type="fn" rid="jah33961-note-0007">a</xref>
</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="2" colspan="1"><italic>P</italic><sub>interaction</sub>=0.082</td>
                        <td align="left" rowspan="1" colspan="1">Resolving ECG LVH</td>
                        <td align="left" rowspan="1" colspan="1">0.69 (0.38‐1.28)</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Progressing ECG LVH</td>
                        <td align="left" rowspan="1" colspan="1">1.95 (0.93‐3.50)</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="3" colspan="1">Amlodipine</td>
                        <td align="left" rowspan="1" colspan="1">Evolving ECG LVH (reference: none)</td>
                        <td align="left" rowspan="1" colspan="1">1.41 (1.26‐1.61)</td>
                        <td align="left" rowspan="1" colspan="1">1.40 (1.25‐1.61)</td>
                        <td align="left" rowspan="1" colspan="1">1.40 (1.25‐1.61)</td>
                        <td align="left" rowspan="1" colspan="1">0.999 (0.995‐1.002)</td>
                        <td align="left" rowspan="1" colspan="1">−0.2 (NS)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Resolving ECG LVH</td>
                        <td align="left" rowspan="1" colspan="1">1.73 (0.85‐3.30)</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Progressing ECG LVH</td>
                        <td align="left" rowspan="1" colspan="1">1.14 (0.60‐2.26)</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="3" colspan="1">Lisinopril</td>
                        <td align="left" rowspan="1" colspan="1">Evolving ECG LVH (reference: none)</td>
                        <td align="left" rowspan="1" colspan="1">1.17 (1.02‐1.32)</td>
                        <td align="left" rowspan="1" colspan="1">1.17 (1.02‐1.32)</td>
                        <td align="left" rowspan="1" colspan="1">1.17 (1.03‐1.32)</td>
                        <td align="left" rowspan="1" colspan="1">0.999 (0.992‐1.003)</td>
                        <td align="left" rowspan="1" colspan="1">−0.9 (NS)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Resolving ECG LVH</td>
                        <td align="left" rowspan="1" colspan="1">1.83 (0.80‐4.10)</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Progressing ECG LVH</td>
                        <td align="left" rowspan="1" colspan="1">0.75 (0.31‐1.63)</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Doxazosin</td>
                        <td align="left" rowspan="1" colspan="1">SBP change Reference Q2 (−3 to −19 mm Hg)</td>
                        <td align="left" rowspan="1" colspan="1">1.16 (1.02‐1.33)</td>
                        <td align="left" rowspan="1" colspan="1">1.17 (1.01‐1.35)</td>
                        <td align="left" rowspan="1" colspan="1">1.19 (1.03‐1.38)</td>
                        <td align="left" rowspan="1" colspan="1">0.98 (0.97‐0.99)</td>
                        <td align="left" rowspan="1" colspan="1">−12.0<xref ref-type="fn" rid="jah33961-note-0007">a</xref>
</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="2" colspan="1"><italic>P</italic><sub>interaction</sub>&lt;0.0001</td>
                        <td align="left" rowspan="1" colspan="1">Q1 (−20 to −80 mm Hg)</td>
                        <td align="left" rowspan="1" colspan="1">1.56 (1.22‐1.87)</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Q3 (−2 to +99 mm Hg)</td>
                        <td align="left" rowspan="1" colspan="1">0.87 (0.70‐1.09)</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="3" colspan="1">Amlodipine</td>
                        <td align="left" rowspan="1" colspan="1">SBP change Reference Q2 (−3 to −19 mm Hg)</td>
                        <td align="left" rowspan="1" colspan="1">1.40 (1.25‐1.61)</td>
                        <td align="left" rowspan="1" colspan="1">1.40 (1.25‐1.61)</td>
                        <td align="left" rowspan="1" colspan="1">1.40 (1.25‐1.61)</td>
                        <td align="left" rowspan="1" colspan="1">1.00 (0.997‐1.008)</td>
                        <td align="left" rowspan="1" colspan="1">+0.3 (NS)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Q1 (−20 to −90 mm Hg)</td>
                        <td align="left" rowspan="1" colspan="1">1.47 (1.22‐1.80)</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Q3 (−2 to +90 mm Hg mm Hg)</td>
                        <td align="left" rowspan="1" colspan="1">1.33 (1.07‐1.61)</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="3" colspan="1">Lisinopril</td>
                        <td align="left" rowspan="1" colspan="1">SBP change Reference Q2 (−3 to −19 mm Hg)</td>
                        <td align="left" rowspan="1" colspan="1">1.17 (1.02‐1.32)</td>
                        <td align="left" rowspan="1" colspan="1">1.17 (1.03‐1.32)</td>
                        <td align="left" rowspan="1" colspan="1">1.17 (1.03‐1.32)</td>
                        <td align="left" rowspan="1" colspan="1">0.99997 (0.998‐1.002)</td>
                        <td align="left" rowspan="1" colspan="1">−0.1 (NS)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Q1 (−20 to −88 mm Hg)</td>
                        <td align="left" rowspan="1" colspan="1">1.18 (0.97‐1.43)</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Q3 (−2 to +107 mm Hg)</td>
                        <td align="left" rowspan="1" colspan="1">1.17 (0.95‐1.44)</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="3" colspan="1">Doxazosin</td>
                        <td align="left" rowspan="1" colspan="1">DBP change Reference Q2 (−2 to −11 mm Hg)</td>
                        <td align="left" rowspan="1" colspan="1">1.15 (0.98‐1.30)</td>
                        <td align="left" rowspan="1" colspan="1">1.19 (1.02‐1.35)</td>
                        <td align="left" rowspan="1" colspan="1">1.17 (0.998‐1.33)</td>
                        <td align="left" rowspan="1" colspan="1">1.02 (1.007‐1.028)</td>
                        <td align="left" rowspan="1" colspan="1">+9.9<xref ref-type="fn" rid="jah33961-note-0007">a</xref>
</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Q1 (−12 to −60 mm Hg)</td>
                        <td align="left" rowspan="1" colspan="1">1.38 (1.08‐1.67)</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Q3 (−1 to +56 mm Hg)</td>
                        <td align="left" rowspan="1" colspan="1">0.96 (0.75‐1.22)</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="3" colspan="1">Amlodipine</td>
                        <td align="left" rowspan="1" colspan="1">DBP change Reference Q2 (−2 to −11 mm Hg)</td>
                        <td align="left" rowspan="1" colspan="1">1.38 (1.23‐1.59)</td>
                        <td align="left" rowspan="1" colspan="1">1.41 (1.26‐1.62)</td>
                        <td align="left" rowspan="1" colspan="1">1.38 (1.23‐1.59)</td>
                        <td align="left" rowspan="1" colspan="1">1.02 (1.003‐1.037)</td>
                        <td align="left" rowspan="1" colspan="1">+6.9<xref ref-type="fn" rid="jah33961-note-0007">a</xref>
</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Q1 (−12 to −69 mm Hg)</td>
                        <td align="left" rowspan="1" colspan="1">1.36 (1.15‐1.65)</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Q3 (−1 to +40 mmHg)</td>
                        <td align="left" rowspan="1" colspan="1">1.40 (1.14‐1.70)</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="3" colspan="1">Lisinopril</td>
                        <td align="left" rowspan="1" colspan="1">DBP change Reference Q2 (−2 to −11 mm Hg)</td>
                        <td align="left" rowspan="1" colspan="1">1.16 (1.02‐1.31)</td>
                        <td align="left" rowspan="1" colspan="1">1.17 (1.03‐1.32)</td>
                        <td align="left" rowspan="1" colspan="1">1.16 (1.01‐1.31)</td>
                        <td align="left" rowspan="1" colspan="1">1.01 (0.998‐1.03)</td>
                        <td align="left" rowspan="1" colspan="1">+8.8 (NS)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Q1 (−12 to −59 mm Hg)</td>
                        <td align="left" rowspan="1" colspan="1">1.11 (0.91‐1.35)</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Q3 (−1 to +63 mm Hg)</td>
                        <td align="left" rowspan="1" colspan="1">1.21 (0.99‐1.53)</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn id="jah33961-note-0006">
                      <p>Proportion mediated=DE×(ME−1)/(DE×ME−1), where DE is direct effect and ME is mediated effect. Q1, Q2, Q3 are tertiles of blood pressure change. A controlled direct effect represents the effect of a drug at certain level of mediator (at absent evolving ECG LVH/progressing/resolving ECG LVH, and at tertiles of BP changes), allowing measurement of interaction between treatment and a mediator. BP indicates blood pressure; DBP, diastolic BP; LVH, left ventricular hypertrophy; RR, relative risk; SBP, systolic BP.</p>
                    </fn>
                    <fn id="jah33961-note-0007">
                      <label>a</label>
                      <p><italic>P</italic>&lt;0.05.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="jah33961-sec-0024">
                <title>Mediation of HF Risk by Dynamic BP Changes</title>
                <p>After full adjustment for confounders, SBP lowering mediated 12% of the effect of doxazosin on HF (Table <xref rid="jah33961-tbl-0004" ref-type="table">4</xref>). Of note, the direct and mediated effects of doxazosin on HF were in opposite directions: the direct effect of doxazosin increased HF risk, whereas the SBP‐lowering–mediated effect reduced HF risk by 12%. There was significant (<italic>P</italic>&lt;0.0001) interaction between doxazosin treatment and mediator: SBP‐lowering in Q1 and Q2 was associated with increased risk of HF, whereas Q3 SBP change (mean increase 11 mm Hg) was protective. The effects of amlodipine and lisinopril on HF were entirely independent of SBP changes.</p>
                <p>DBP lowering mediated 10% of the effect of doxazosin, 7% of the effect of amlodipine, and 9% of the effect of lisinopril on HF. In fully adjusted analyses (Table <xref rid="jah33961-tbl-0004" ref-type="table">4</xref>), mediation of the effect of lisinopril lost statistical significance. Both direct and mediated pathways had the same direction and contributed to the increased HF risk.</p>
                <p>Sensitivity analyses with different definitions of BP lowering provided similar results (Table <xref rid="jah33961-tbl-0005" ref-type="table">5</xref>). The fastest SBP‐lowering mediated ≈13% of the effect of lisinopril on HF.</p>
                <table-wrap id="jah33961-tbl-0005" xml:lang="en" orientation="portrait" position="float">
                  <label>Table 5</label>
                  <caption>
                    <p>Effect of Antihypertensive Treatment on Incident Symptomatic Heart Failure (Total), Through Relative “Greatest” BP Changes, Absolute and Relative “Fastest” BP Changes (Mediated), and Independent of BP Lowering (Direct)</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <thead valign="top">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="top" rowspan="1" colspan="1"/>
                        <th align="left" valign="top" rowspan="1" colspan="1">Treatment</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">Mediator</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">Total Effect RR (95% CI)</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">Controlled Direct Effect RR (95% CI)</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">Direct Effect RR (95% CI)</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">Mediated Effect RR (95% CI)</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">% Mediated</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="6" colspan="1">Relative greatest BP lowering</td>
                        <td align="left" rowspan="1" colspan="1">Doxazosin</td>
                        <td align="left" rowspan="1" colspan="1">SBP change Q2</td>
                        <td align="left" rowspan="1" colspan="1">1.17 (0.9996‐1.32)</td>
                        <td align="left" rowspan="1" colspan="1">1.16 (1.00‐1.32)</td>
                        <td align="left" rowspan="1" colspan="1">1.19 (1.02‐1.35)</td>
                        <td align="left" rowspan="1" colspan="1">0.98 (0.97‐0.99)</td>
                        <td align="left" rowspan="1" colspan="1">−13.7<xref ref-type="fn" rid="jah33961-note-0009">a</xref>
</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Amlodipine</td>
                        <td align="left" rowspan="1" colspan="1">SBP change Q2</td>
                        <td align="left" rowspan="1" colspan="1">1.40 (1.25‐1.61)</td>
                        <td align="left" rowspan="1" colspan="1">1.39 (1.25‐1.61)</td>
                        <td align="left" rowspan="1" colspan="1">1.40 (1.25‐1.61)</td>
                        <td align="left" rowspan="1" colspan="1">1.003 (0.998‐1.01)</td>
                        <td align="left" rowspan="1" colspan="1">+1.1 (NS)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Lisinopril</td>
                        <td align="left" rowspan="1" colspan="1">SBP change Q2</td>
                        <td align="left" rowspan="1" colspan="1">1.17 (1.03‐1.32)</td>
                        <td align="left" rowspan="1" colspan="1">1.17 (1.02‐1.32)</td>
                        <td align="left" rowspan="1" colspan="1">1.17 (1.02‐1.32)</td>
                        <td align="left" rowspan="1" colspan="1">1.00 (0.997‐1.003)</td>
                        <td align="left" rowspan="1" colspan="1">+0.02 (NS)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Doxazosin</td>
                        <td align="left" rowspan="1" colspan="1">DBP change Q2</td>
                        <td align="left" rowspan="1" colspan="1">1.19 (1.02‐1.35)</td>
                        <td align="left" rowspan="1" colspan="1">1.16 (0.99‐1.31)</td>
                        <td align="left" rowspan="1" colspan="1">1.17 (0.998‐1.33)</td>
                        <td align="left" rowspan="1" colspan="1">1.01 (1.006‐1.03)</td>
                        <td align="left" rowspan="1" colspan="1">+9.3<xref ref-type="fn" rid="jah33961-note-0009">a</xref>
</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Amlodipine</td>
                        <td align="left" rowspan="1" colspan="1">DBP change Q2</td>
                        <td align="left" rowspan="1" colspan="1">1.41 (1.26‐1.62)</td>
                        <td align="left" rowspan="1" colspan="1">1.38 (1.23‐1.59)</td>
                        <td align="left" rowspan="1" colspan="1">1.38 (1.23‐1.59)</td>
                        <td align="left" rowspan="1" colspan="1">1.02 (1.001‐1.04)</td>
                        <td align="left" rowspan="1" colspan="1">+7.0<xref ref-type="fn" rid="jah33961-note-0009">a</xref>
</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Lisinopril</td>
                        <td align="left" rowspan="1" colspan="1">DBP change Q2</td>
                        <td align="left" rowspan="1" colspan="1">1.17 (1.03‐1.32)</td>
                        <td align="left" rowspan="1" colspan="1">1.16 (1.02‐1.31)</td>
                        <td align="left" rowspan="1" colspan="1">1.16 (1.01‐1.31)</td>
                        <td align="left" rowspan="1" colspan="1">1.01 (0.998‐1.03)</td>
                        <td align="left" rowspan="1" colspan="1">+8.8 (NS)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="6" colspan="1">Fastest BP lowering</td>
                        <td align="left" rowspan="1" colspan="1">Doxazosin</td>
                        <td align="left" rowspan="1" colspan="1">SBP change Q2</td>
                        <td align="left" rowspan="1" colspan="1">1.17 (1.01‐1.34)</td>
                        <td align="left" rowspan="1" colspan="1">1.16 (0.998‐1.32)</td>
                        <td align="left" rowspan="1" colspan="1">1.16 (0.996‐1.32)</td>
                        <td align="left" rowspan="1" colspan="1">1.008 (0.994‐1.25)</td>
                        <td align="left" rowspan="1" colspan="1">+5.6 (NS)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Amlodipine</td>
                        <td align="left" rowspan="1" colspan="1">SBP change Q2</td>
                        <td align="left" rowspan="1" colspan="1">1.40 (1.26‐1.62)</td>
                        <td align="left" rowspan="1" colspan="1">1.39 (1.25‐1.60)</td>
                        <td align="left" rowspan="1" colspan="1">1.39 (1.25‐1.60)</td>
                        <td align="left" rowspan="1" colspan="1">1.006 (0.9995‐1.01)</td>
                        <td align="left" rowspan="1" colspan="1">+2.2 (NS)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Lisinopril</td>
                        <td align="left" rowspan="1" colspan="1">SBP change Q2</td>
                        <td align="left" rowspan="1" colspan="1">1.17 (1.02‐1.32)</td>
                        <td align="left" rowspan="1" colspan="1">1.15 (1.0005‐1.29)</td>
                        <td align="left" rowspan="1" colspan="1">1.15 (0.999‐1.29)</td>
                        <td align="left" rowspan="1" colspan="1">1.02 (1.009‐1.04)</td>
                        <td align="left" rowspan="1" colspan="1">+13.7<xref ref-type="fn" rid="jah33961-note-0009">a</xref>
</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Doxazosin</td>
                        <td align="left" rowspan="1" colspan="1">DBP change Q2</td>
                        <td align="left" rowspan="1" colspan="1">1.18 (1.01‐1.34)</td>
                        <td align="left" rowspan="1" colspan="1">1.18 (1.01‐1.34)</td>
                        <td align="left" rowspan="1" colspan="1">1.18 (1.01‐1.33)</td>
                        <td align="left" rowspan="1" colspan="1">1.0005 (0.999‐1.005)</td>
                        <td align="left" rowspan="1" colspan="1">+0.3 (NS)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Amlodipine</td>
                        <td align="left" rowspan="1" colspan="1">DBP change Q2</td>
                        <td align="left" rowspan="1" colspan="1">1.41 (1.25‐1.62)</td>
                        <td align="left" rowspan="1" colspan="1">1.39 (1.24‐1.60)</td>
                        <td align="left" rowspan="1" colspan="1">1.40 (1.25‐1.61)</td>
                        <td align="left" rowspan="1" colspan="1">1.004 (0.998‐1.01)</td>
                        <td align="left" rowspan="1" colspan="1">+1.2 (NS)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Lisinopril</td>
                        <td align="left" rowspan="1" colspan="1">DBP change Q2</td>
                        <td align="left" rowspan="1" colspan="1">1.17 (1.02‐1.32)</td>
                        <td align="left" rowspan="1" colspan="1">1.17 (1.02‐1.32)</td>
                        <td align="left" rowspan="1" colspan="1">1.17 (1.02‐1.31)</td>
                        <td align="left" rowspan="1" colspan="1">1.001 (0.9996‐1.006)</td>
                        <td align="left" rowspan="1" colspan="1">+0.9 (NS)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="6" colspan="1">Relative fastest BP lowering</td>
                        <td align="left" rowspan="1" colspan="1">Doxazosin</td>
                        <td align="left" rowspan="1" colspan="1">SBP change Q2</td>
                        <td align="left" rowspan="1" colspan="1">1.17 (1.01‐1.34)</td>
                        <td align="left" rowspan="1" colspan="1">1.16 (0.998‐1.32)</td>
                        <td align="left" rowspan="1" colspan="1">1.16 (0.995‐1.33)</td>
                        <td align="left" rowspan="1" colspan="1">1.01 (0.994‐1.03)</td>
                        <td align="left" rowspan="1" colspan="1">+6.3 (NS)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Amlodipine</td>
                        <td align="left" rowspan="1" colspan="1">SBP change Q2</td>
                        <td align="left" rowspan="1" colspan="1">1.40 (1.26‐1.60)</td>
                        <td align="left" rowspan="1" colspan="1">1.39 (1.25‐1.60)</td>
                        <td align="left" rowspan="1" colspan="1">1.39 (1.25‐1.60)</td>
                        <td align="left" rowspan="1" colspan="1">1.007 (0.99993‐1.02)</td>
                        <td align="left" rowspan="1" colspan="1">+2.4 (NS)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Lisinopril</td>
                        <td align="left" rowspan="1" colspan="1">SBP change Q2</td>
                        <td align="left" rowspan="1" colspan="1">1.17 (1.02‐1.32)</td>
                        <td align="left" rowspan="1" colspan="1">1.15 (1.003‐1.29)</td>
                        <td align="left" rowspan="1" colspan="1">1.15 (0.999‐1.29)</td>
                        <td align="left" rowspan="1" colspan="1">1.02 (1.009‐1.035)</td>
                        <td align="left" rowspan="1" colspan="1">+13.4<xref ref-type="fn" rid="jah33961-note-0009">a</xref>
</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Doxazosin</td>
                        <td align="left" rowspan="1" colspan="1">DBP change Q2</td>
                        <td align="left" rowspan="1" colspan="1">1.18 (1.01‐1.33)</td>
                        <td align="left" rowspan="1" colspan="1">1.18 (1.01‐1.34)</td>
                        <td align="left" rowspan="1" colspan="1">1.18 (1.01‐1.33)</td>
                        <td align="left" rowspan="1" colspan="1">1.0001 (0.999‐1.003)</td>
                        <td align="left" rowspan="1" colspan="1">+0.1 (NS)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Amlodipine</td>
                        <td align="left" rowspan="1" colspan="1">DBP change Q2</td>
                        <td align="left" rowspan="1" colspan="1">1.40 (1.26‐1.62)</td>
                        <td align="left" rowspan="1" colspan="1">1.40 (1.25‐1.61)</td>
                        <td align="left" rowspan="1" colspan="1">1.40 (1.25‐1.61)</td>
                        <td align="left" rowspan="1" colspan="1">1.003 (0.997‐1.01)</td>
                        <td align="left" rowspan="1" colspan="1">+1.05 (NS)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Lisinopril</td>
                        <td align="left" rowspan="1" colspan="1">DBP change Q2</td>
                        <td align="left" rowspan="1" colspan="1">1.17 (1.02‐1.32)</td>
                        <td align="left" rowspan="1" colspan="1">1.17 (1.02‐1.33)</td>
                        <td align="left" rowspan="1" colspan="1">1.17 (1.02‐1.32)</td>
                        <td align="left" rowspan="1" colspan="1">1.0006 (0.9994‐1.005)</td>
                        <td align="left" rowspan="1" colspan="1">+0.4 (NS)</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn id="jah33961-note-0008">
                      <p>Proportion mediated=DE×(ME−1)/(DE×ME−1), where DE is direct effect and ME is mediated effect. Q2 is a medium tertile of blood pressure changes. A controlled direct effect represents the effect of a drug at the second tertile of BP changes. BP indicates blood pressure; DBP, diastolic blood pressure; NS, nonsignificant; RR, relative risk; SBP, systolic blood pressure.</p>
                    </fn>
                    <fn id="jah33961-note-0009">
                      <label>a</label>
                      <p><italic>P</italic>&lt;0.05.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
            </sec>
            <sec id="jah33961-sec-0025">
              <title>Discussion</title>
              <p>The main finding of our study is that evolving ECG LVH and BP lowering explain up to 13% of the HF‐preventive effect of the diuretic chlorthalidone as compared with the preventive effect of antihypertensive treatment with the α‐blocker doxazosin, the angiotensin‐converting enzyme inhibitor lisinopril, and the calcium channel blocker amlodipine. This finding highlights the notion of HF as a complex multifactorial condition and underscores the importance of the use of diuretics for HF prevention, which targets mechanisms that are largely independent of BP lowering and evolving ECG LVH.</p>
              <sec id="jah33961-sec-0026">
                <title>Heart Failure Prevention in Hypertension</title>
                <p>HTN is the major risk factor of HF, associated with 2‐ to 3‐fold increased HF incidence in observational cohort studies.<xref rid="jah33961-bib-0018" ref-type="ref">18</xref> However, in randomized controlled trials HTN treatment is associated with only 20% to 25% reduction in HF risk.<xref rid="jah33961-bib-0005" ref-type="ref">5</xref> Our study provided consistent findings: BP lowering mediated only up to 13% of the effect of antihypertensive medications on incident HF. Such a disconnect between a risk factor and the effect of its modification is traditionally explained by poor BP control, irreversible damage of the heart over long‐time risk exposure, insufficient awareness of HTN, and inadequate assessment of HTN by a single BP measurement. Our study findings suggest that in order to achieve the most effective HF prevention, BP lowering should not be the only criterion of HTN treatment effectiveness. Moreover, because different antihypertensive treatments have different mediators, different criteria of effectiveness (beyond BP control) should be developed for each class of antihypertensive drugs.</p>
              </sec>
              <sec id="jah33961-sec-0027">
                <title>Diuretics for HF Prevention</title>
                <p>Our study showed that the mechanisms by which the thiazide diuretic chlorthalidone prevented HF were not restricted to BP lowering and prevention of LVH. The mechanisms responsible for the favorable effect of chlorthalidone on HF prevention in people with HTN are unknown. In addition to BP lowering, chlorthalidone has pleiotropic effects including improving endothethial function and reducing inflammation and oxidative stress.<xref rid="jah33961-bib-0019" ref-type="ref">19</xref> Better understanding of the mechanisms behind the effect of chlorthalidone on HF may lead to new drug formulations specifically targeting HF prevention in patients with HTN.</p>
              </sec>
              <sec id="jah33961-sec-0028">
                <title>Left Ventricular Hypertrophy and Heart Failure</title>
                <p>Long‐standing HTN and LVH can start a devastating cascade that leads to HF via myocyte growth, oxidative stress, and fibrosis.<xref rid="jah33961-bib-0020" ref-type="ref">20</xref> Although antihypertensive drugs have been shown to reduce and even reverse LVH, this study showed that reduction in ECG LVH increased the risk of HF, as compared with patients who remained free from LVH.</p>
                <p>In the current study, evolving LVH mediated only 4% of the effect of doxazosin on HF. Consistent with our findings, previous analysis of Cornell voltage changes during the ALLHAT trial<xref rid="jah33961-bib-0021" ref-type="ref">21</xref> showed no difference in ECG LVH development/resolution between the amlodipine, lisinopril, or chlorthalidone treatment arms. There are known limitations of ECG LVH as a measure of the LV enlargement, as there are more than a dozen ECG LVH definitions with poor agreement among them.<xref rid="jah33961-bib-0022" ref-type="ref">22</xref> Differences between LVH measured by ECG and LV mass measured by imaging modalities<xref rid="jah33961-bib-0022" ref-type="ref">22</xref> reflect true differences between the cardiac anatomy and the electrophysiological substrate. ECG LVH characterizes an abnormal electrophysiological substrate, which is associated with sudden cardiac death and incident HF independent of LV mass and BP control.<xref rid="jah33961-bib-0023" ref-type="ref">23</xref>, <xref rid="jah33961-bib-0024" ref-type="ref">24</xref>, <xref rid="jah33961-bib-0025" ref-type="ref">25</xref> Additional ECG measures of electrophysiological substrate should be considered as potential mediators of antihypertensive treatment effect on HF. For example, the sum absolute QRST integral was shown to be associated with HF hospitalization or death in the MADIT II (Multicenter Automatic Defibrillator Implantation Trial II) study.<xref rid="jah33961-bib-0026" ref-type="ref">26</xref> Longitudinal changes in global electrical heterogeneity were associated with LV dysfunction.<xref rid="jah33961-bib-0027" ref-type="ref">27</xref> Comprehensive description of electrophysiological substrate beyond evolving LVH (eg, using the sum absolute QRST integral and global electrical heterogeneity) may improve understanding of the mechanisms responsible for HF development in the setting of HTN.</p>
              </sec>
              <sec id="jah33961-sec-0029">
                <title>Blood Pressure Lowering and Heart Failure</title>
                <p>Our findings are largely consistent with previous ALLHAT results and conclusions.<xref rid="jah33961-bib-0028" ref-type="ref">28</xref> Previous analysis of attributable risks due to BP lowering<xref rid="jah33961-bib-0029" ref-type="ref">29</xref> concluded that the effect of amlodipine on incident HF was BP independent, whereas BP lowering only partially explained the effect of lisinopril on HF. In our adjusted mediation analysis, the effect of both amlodipine and lisinopril on HF was entirely independent of SBP, whereas DBP lowering mediated 7% of the effect of amlodipine and 9% of the effect of lisinopril. Interestingly, we observed opposite directions of the direct effect of doxazosin (increased HF risk) and SBP‐lowering–mediated effect of doxazosin (reduced HF risk by 12%). DBP lowering mediated 10% of the effect of doxazosin and had the same direction as the direct effect of doxazosin. Because doxazosin remains a viable HTN treatment option for men with benign prostatic hyperplasia, complex effects of BP lowering on incident HF should be taken into account for patients on doxazosin. Overall, the very modest effect of BP lowering on incident HF highlights the importance of additional (beyond BP control) biomarkers for the assessment of effectiveness of antihypertensive drugs for HF prevention.</p>
              </sec>
              <sec id="jah33961-sec-0030">
                <title>Strengths and Limitations</title>
                <p>ALLHAT is the largest randomized controlled trial of antihypertensive treatment, allowing unbiased mediation analysis and strengthening 2 major assumptions of mediation analysis. Randomization eliminated exposure‐outcome and exposure‐mediator confounding. However, limitations of this study should be taken into account. Although we adjusted for known common causes of evolving ECG LVH, BP lowering, and incident HF, unmeasured confounding can affect the study estimates. ALLHAT enrolled high‐risk HTN patients, and thus the results of this study may not be generalizable to lower‐risk populations. In our study baseline BP displayed moderate correlation with in‐trial BP lowering (Figure <xref rid="jah33961-fig-0003" ref-type="fig">3</xref>), which at least partially explained the U‐shaped association of BP‐lowering with incident HF. We utilized modeling approaches that accounted for nonlinear associations, but it is possible that we underestimated the true effect of BP lowering on incident HF.</p>
              </sec>
            </sec>
            <sec id="jah33961-sec-0032">
              <title>Sources of Funding</title>
              <p>This work was partially supported by National Heart, Lung, and Blood Institute grant HL118277 to Tereshchenko. The ALLHAT study was supported by the National Heart, Lung, and Blood Institute (NO1‐HC‐35130). ALLHAT investigators received contributions of study medications supplied by Pfizer (amlodipine and doxazosin), AstraZeneca (atenolol and lisinopril), and Bristol‐Myers Squibb (pravastatin) and financial support provided by Pfizer.</p>
            </sec>
            <sec id="jah33961-sec-0033">
              <title>Disclosures</title>
              <p>None.</p>
            </sec>
          </body>
          <back>
            <ack id="jah33961-sec-0031">
              <title>Acknowledgments</title>
              <p>This article was prepared using ALLHAT Research Materials obtained from the National Heart, Lung, and Blood Institute Biologic Specimen and Data Repository Information Coordinating Center.</p>
            </ack>
            <ref-list content-type="cited-references" id="jah33961-bibl-0001">
              <title>References</title>
              <ref id="jah33961-bib-0001">
                <label>1</label>
                <mixed-citation publication-type="journal" id="jah33961-cit-0001"><string-name><surname>Rapsomaniki</surname><given-names>E</given-names></string-name>, <string-name><surname>Timmis</surname><given-names>A</given-names></string-name>, <string-name><surname>George</surname><given-names>J</given-names></string-name>, <string-name><surname>Pujades‐Rodriguez</surname><given-names>M</given-names></string-name>, <string-name><surname>Shah</surname><given-names>AD</given-names></string-name>, <string-name><surname>Denaxas</surname><given-names>S</given-names></string-name>, <string-name><surname>White</surname><given-names>IR</given-names></string-name>, <string-name><surname>Caulfield</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Deanfield</surname><given-names>JE</given-names></string-name>, <string-name><surname>Smeeth</surname><given-names>L</given-names></string-name>, <string-name><surname>Williams</surname><given-names>B</given-names></string-name>, <string-name><surname>Hingorani</surname><given-names>A</given-names></string-name>, <string-name><surname>Hemingway</surname><given-names>H</given-names></string-name>. <article-title>Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life‐years lost, and age‐specific associations in 1.25 million people</article-title>. <source xml:lang="en">Lancet</source>. <year>2014</year>;<volume>383</volume>:<fpage>1899</fpage>–<lpage>1911</lpage>.<pub-id pub-id-type="pmid">24881994</pub-id></mixed-citation>
              </ref>
              <ref id="jah33961-bib-0002">
                <label>2</label>
                <mixed-citation publication-type="journal" id="jah33961-cit-0002"><string-name><surname>Zanchetti</surname><given-names>A</given-names></string-name>. <article-title>Hypertension: cardiac hypertrophy as a target of antihypertensive therapy</article-title>. <source xml:lang="en">Nat Rev Cardiol</source>. <year>2010</year>;<volume>7</volume>:<fpage>66</fpage>–<lpage>67</lpage>.<pub-id pub-id-type="pmid">20104240</pub-id></mixed-citation>
              </ref>
              <ref id="jah33961-bib-0003">
                <label>3</label>
                <mixed-citation publication-type="journal" id="jah33961-cit-0003"><string-name><surname>Psaty</surname><given-names>BM</given-names></string-name>, <string-name><surname>Smith</surname><given-names>NL</given-names></string-name>, <string-name><surname>Siscovick</surname><given-names>DS</given-names></string-name>, <string-name><surname>Koepsell</surname><given-names>TD</given-names></string-name>, <string-name><surname>Weiss</surname><given-names>NS</given-names></string-name>, <string-name><surname>Heckbert</surname><given-names>SR</given-names></string-name>, <string-name><surname>Lemaitre</surname><given-names>RN</given-names></string-name>, <string-name><surname>Wagner</surname><given-names>EH</given-names></string-name>, <string-name><surname>Furberg</surname><given-names>CD</given-names></string-name>. <article-title>Health outcomes associated with antihypertensive therapies used as first‐line agents. A systematic review and meta‐analysis</article-title>. <source xml:lang="en">JAMA</source>. <year>1997</year>;<volume>277</volume>:<fpage>739</fpage>–<lpage>745</lpage>.<pub-id pub-id-type="pmid">9042847</pub-id></mixed-citation>
              </ref>
              <ref id="jah33961-bib-0004">
                <label>4</label>
                <mixed-citation publication-type="journal" id="jah33961-cit-0004"><string-name><surname>Whelton</surname><given-names>PK</given-names></string-name>, <string-name><surname>Carey</surname><given-names>RM</given-names></string-name>, <string-name><surname>Aronow</surname><given-names>WS</given-names></string-name>, <string-name><surname>Casey</surname><given-names>DE</given-names></string-name>, <string-name><surname>Collins</surname><given-names>KJ</given-names></string-name>, <string-name><surname>Dennison Himmelfarb</surname><given-names>C</given-names></string-name>, <string-name><surname>DePalma</surname><given-names>SM</given-names></string-name>, <string-name><surname>Gidding</surname><given-names>S</given-names></string-name>, <string-name><surname>Jamerson</surname><given-names>KA</given-names></string-name>, <string-name><surname>Jones</surname><given-names>DW</given-names></string-name>, <string-name><surname>MacLaughlin</surname><given-names>EJ</given-names></string-name>, <string-name><surname>Muntner</surname><given-names>P</given-names></string-name>, <string-name><surname>Ovbiagele</surname><given-names>B</given-names></string-name>, <string-name><surname>Smith</surname><given-names>SC</given-names></string-name>, <string-name><surname>Spencer</surname><given-names>CC</given-names></string-name>, <string-name><surname>Stafford</surname><given-names>RS</given-names></string-name>, <string-name><surname>Taler</surname><given-names>SJ</given-names></string-name>, <string-name><surname>Thomas</surname><given-names>RJ</given-names></string-name>, <string-name><surname>Williams</surname><given-names>KA</given-names></string-name>, <string-name><surname>Williamson</surname><given-names>JD</given-names></string-name>, <string-name><surname>Wright</surname><given-names>JT</given-names></string-name>. <article-title>2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APHA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines</article-title>. <source xml:lang="en">J Am Coll Cardiol</source>. <year>2018</year>;<volume>71</volume>:<fpage>e127</fpage>–<lpage>e248</lpage>.<pub-id pub-id-type="pmid">29146535</pub-id></mixed-citation>
              </ref>
              <ref id="jah33961-bib-0005">
                <label>5</label>
                <mixed-citation publication-type="journal" id="jah33961-cit-0005"><string-name><surname>Law</surname><given-names>MR</given-names></string-name>, <string-name><surname>Morris</surname><given-names>JK</given-names></string-name>, <string-name><surname>Wald</surname><given-names>NJ</given-names></string-name>. <article-title>Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta‐analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies</article-title>. <source xml:lang="en">BMJ</source>. <year>2009</year>;<volume>338</volume>:<fpage>b1665</fpage>.<pub-id pub-id-type="pmid">19454737</pub-id></mixed-citation>
              </ref>
              <ref id="jah33961-bib-0006">
                <label>6</label>
                <mixed-citation publication-type="journal" id="jah33961-cit-0006"><string-name><surname>Davis</surname><given-names>BR</given-names></string-name>, <string-name><surname>Cutler</surname><given-names>JA</given-names></string-name>, <string-name><surname>Gordon</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Furberg</surname><given-names>CD</given-names></string-name>, <string-name><surname>Wright</surname><given-names>JT</given-names><suffix>Jr</suffix></string-name>, <string-name><surname>Cushman</surname><given-names>WC</given-names></string-name>, <string-name><surname>Grimm</surname><given-names>RH</given-names></string-name>, <string-name><surname>LaRosa</surname><given-names>J</given-names></string-name>, <string-name><surname>Whelton</surname><given-names>PK</given-names></string-name>, <string-name><surname>Perry</surname><given-names>HM</given-names></string-name>, <string-name><surname>Alderman</surname><given-names>MH</given-names></string-name>, <string-name><surname>Ford</surname><given-names>CE</given-names></string-name>, <string-name><surname>Oparil</surname><given-names>S</given-names></string-name>, <string-name><surname>Francis</surname><given-names>C</given-names></string-name>, <string-name><surname>Proschan</surname><given-names>M</given-names></string-name>, <string-name><surname>Pressel</surname><given-names>S</given-names></string-name>, <string-name><surname>Black</surname><given-names>HR</given-names></string-name>, <string-name><surname>Hawkins</surname><given-names>CM</given-names></string-name>. <article-title>Rationale and design for the antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Research Group</article-title>. <source xml:lang="en">Am J Hypertens</source>. <year>1996</year>;<volume>9</volume>:<fpage>342</fpage>–<lpage>360</lpage>.<pub-id pub-id-type="pmid">8722437</pub-id></mixed-citation>
              </ref>
              <ref id="jah33961-bib-0007">
                <label>7</label>
                <mixed-citation publication-type="journal" id="jah33961-cit-0007"><string-name><surname>Schmieder</surname><given-names>RE</given-names></string-name>, <string-name><surname>Martus</surname><given-names>P</given-names></string-name>, <string-name><surname>Klingbeil</surname><given-names>A</given-names></string-name>. <article-title>Reversal of left ventricular hypertrophy in essential hypertension. A meta‐analysis of randomized double‐blind studies</article-title>. <source xml:lang="en">JAMA</source>. <year>1996</year>;<volume>275</volume>:<fpage>1507</fpage>–<lpage>1513</lpage>.<pub-id pub-id-type="pmid">8622227</pub-id></mixed-citation>
              </ref>
              <ref id="jah33961-bib-0008">
                <label>8</label>
                <mixed-citation publication-type="journal" id="jah33961-cit-0008"><article-title>Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid‐lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group</article-title>. <source xml:lang="en">JAMA</source>. <year>2000</year>;<volume>283</volume>:<fpage>1967</fpage>–<lpage>1975</lpage>.<pub-id pub-id-type="pmid">10789664</pub-id></mixed-citation>
              </ref>
              <ref id="jah33961-bib-0009">
                <label>9</label>
                <mixed-citation publication-type="journal" id="jah33961-cit-0009"><collab collab-type="authors">ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial</collab>
. <article-title>Major outcomes in high‐risk hypertensive patients randomized to angiotensin‐converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid‐lowering treatment to prevent heart attack trial (ALLHAT)</article-title>. <source xml:lang="en">JAMA</source>. <year>2002</year>;<volume>288</volume>:<fpage>2981</fpage>–<lpage>2997</lpage>.<pub-id pub-id-type="pmid">12479763</pub-id></mixed-citation>
              </ref>
              <ref id="jah33961-bib-0010">
                <label>10</label>
                <mixed-citation publication-type="journal" id="jah33961-cit-0010"><string-name><surname>Einhorn</surname><given-names>PT</given-names></string-name>, <string-name><surname>Davis</surname><given-names>BR</given-names></string-name>, <string-name><surname>Massie</surname><given-names>BM</given-names></string-name>, <string-name><surname>Cushman</surname><given-names>WC</given-names></string-name>, <string-name><surname>Piller</surname><given-names>LB</given-names></string-name>, <string-name><surname>Simpson</surname><given-names>LM</given-names></string-name>, <string-name><surname>Levy</surname><given-names>D</given-names></string-name>, <string-name><surname>Nwachuku</surname><given-names>CE</given-names></string-name>, <string-name><surname>Black</surname><given-names>HR</given-names></string-name>. <article-title>The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) heart failure validation study: diagnosis and prognosis</article-title>. <source xml:lang="en">Am Heart J</source>. <year>2007</year>;<volume>153</volume>:<fpage>42</fpage>–<lpage>53</lpage>.<pub-id pub-id-type="pmid">17174636</pub-id></mixed-citation>
              </ref>
              <ref id="jah33961-bib-0011">
                <label>11</label>
                <mixed-citation publication-type="journal" id="jah33961-cit-0011"><string-name><surname>Davis</surname><given-names>BR</given-names></string-name>, <string-name><surname>Kostis</surname><given-names>JB</given-names></string-name>, <string-name><surname>Simpson</surname><given-names>LM</given-names></string-name>, <string-name><surname>Black</surname><given-names>HR</given-names></string-name>, <string-name><surname>Cushman</surname><given-names>WC</given-names></string-name>, <string-name><surname>Einhorn</surname><given-names>PT</given-names></string-name>, <string-name><surname>Farber</surname><given-names>MA</given-names></string-name>, <string-name><surname>Ford</surname><given-names>CE</given-names></string-name>, <string-name><surname>Levy</surname><given-names>D</given-names></string-name>, <string-name><surname>Massie</surname><given-names>BM</given-names></string-name>, <string-name><surname>Nawaz</surname><given-names>S</given-names></string-name>. <article-title>Heart failure with preserved and reduced left ventricular ejection fraction in the Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial</article-title>. <source xml:lang="en">Circulation</source>. <year>2008</year>;<volume>118</volume>:<fpage>2259</fpage>–<lpage>2267</lpage>.<pub-id pub-id-type="pmid">19001024</pub-id></mixed-citation>
              </ref>
              <ref id="jah33961-bib-0012">
                <label>12</label>
                <mixed-citation publication-type="journal" id="jah33961-cit-0012"><string-name><surname>Davis</surname><given-names>BR</given-names></string-name>, <string-name><surname>Piller</surname><given-names>LB</given-names></string-name>, <string-name><surname>Cutler</surname><given-names>JA</given-names></string-name>, <string-name><surname>Furberg</surname><given-names>C</given-names></string-name>, <string-name><surname>Dunn</surname><given-names>K</given-names></string-name>, <string-name><surname>Franklin</surname><given-names>S</given-names></string-name>, <string-name><surname>Goff</surname><given-names>D</given-names></string-name>, <string-name><surname>Leenen</surname><given-names>F</given-names></string-name>, <string-name><surname>Mohiuddin</surname><given-names>S</given-names></string-name>, <string-name><surname>Papademetriou</surname><given-names>V</given-names></string-name>, <string-name><surname>Proschan</surname><given-names>M</given-names></string-name>, <string-name><surname>Ellsworth</surname><given-names>A</given-names></string-name>, <string-name><surname>Golden</surname><given-names>J</given-names></string-name>, <string-name><surname>Colon</surname><given-names>P</given-names></string-name>, <string-name><surname>Crow</surname><given-names>R</given-names></string-name>. <article-title>Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack trial</article-title>. <source xml:lang="en">Circulation</source>. <year>2006</year>;<volume>113</volume>:<fpage>2201</fpage>–<lpage>2210</lpage>.<pub-id pub-id-type="pmid">16651474</pub-id></mixed-citation>
              </ref>
              <ref id="jah33961-bib-0013">
                <label>13</label>
                <mixed-citation publication-type="book" id="jah33961-cit-0013"><string-name><surname>Prineas</surname><given-names>RJ</given-names></string-name>, <string-name><surname>Crow</surname><given-names>RS</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>Z‐M</given-names></string-name>. <source xml:lang="en">The Minnesota Code Manual of Electrocardiographic Findings: Standards and Procedures for Measurement and Classification</source>. <publisher-loc>London</publisher-loc>: <publisher-name>Springer</publisher-name>; <year>2010</year>.</mixed-citation>
              </ref>
              <ref id="jah33961-bib-0014">
                <label>14</label>
                <mixed-citation publication-type="journal" id="jah33961-cit-0014"><string-name><surname>Crow</surname><given-names>RS</given-names></string-name>, <string-name><surname>Prineas</surname><given-names>RJ</given-names></string-name>, <string-name><surname>Hannan</surname><given-names>PJ</given-names></string-name>, <string-name><surname>Grandits</surname><given-names>G</given-names></string-name>, <string-name><surname>Blackburn</surname><given-names>H</given-names></string-name>. <article-title>Prognostic associations of Minnesota Code serial electrocardiographic change classification with coronary heart disease mortality in the Multiple Risk Factor Intervention Trial</article-title>. <source xml:lang="en">Am J Cardiol</source>. <year>1997</year>;<volume>80</volume>:<fpage>138</fpage>–<lpage>144</lpage>.<pub-id pub-id-type="pmid">9230148</pub-id></mixed-citation>
              </ref>
              <ref id="jah33961-bib-0015">
                <label>15</label>
                <mixed-citation publication-type="journal" id="jah33961-cit-0015"><string-name><surname>Robins</surname><given-names>JM</given-names></string-name>, <string-name><surname>Greenland</surname><given-names>S</given-names></string-name>. <article-title>Identifiability and exchangeability for direct and indirect effects</article-title>. <source xml:lang="en">Epidemiology</source>. <year>1992</year>;<volume>3</volume>:<fpage>143</fpage>–<lpage>155</lpage>.<pub-id pub-id-type="pmid">1576220</pub-id></mixed-citation>
              </ref>
              <ref id="jah33961-bib-0016">
                <label>16</label>
                <mixed-citation publication-type="journal" id="jah33961-cit-0016"><string-name><surname>Valeri</surname><given-names>L</given-names></string-name>, <string-name><surname>Vanderweele</surname><given-names>TJ</given-names></string-name>. <article-title>Mediation analysis allowing for exposure‐mediator interactions and causal interpretation: theoretical assumptions and implementation with SAS and SPSS macros</article-title>. <source xml:lang="en">Psychol Methods</source>. <year>2013</year>;<volume>18</volume>:<fpage>137</fpage>–<lpage>150</lpage>.<pub-id pub-id-type="pmid">23379553</pub-id></mixed-citation>
              </ref>
              <ref id="jah33961-bib-0017">
                <label>17</label>
                <mixed-citation publication-type="journal" id="jah33961-cit-0017"><string-name><surname>Piller</surname><given-names>LB</given-names></string-name>, <string-name><surname>Baraniuk</surname><given-names>S</given-names></string-name>, <string-name><surname>Simpson</surname><given-names>LM</given-names></string-name>, <string-name><surname>Cushman</surname><given-names>WC</given-names></string-name>, <string-name><surname>Massie</surname><given-names>BM</given-names></string-name>, <string-name><surname>Einhorn</surname><given-names>PT</given-names></string-name>, <string-name><surname>Oparil</surname><given-names>S</given-names></string-name>, <string-name><surname>Ford</surname><given-names>CE</given-names></string-name>, <string-name><surname>Graumlich</surname><given-names>JF</given-names></string-name>, <string-name><surname>Dart</surname><given-names>RA</given-names></string-name>, <string-name><surname>Parish</surname><given-names>DC</given-names></string-name>, <string-name><surname>Retta</surname><given-names>TM</given-names></string-name>, <string-name><surname>Cuyjet</surname><given-names>AB</given-names></string-name>, <string-name><surname>Jafri</surname><given-names>SZ</given-names></string-name>, <string-name><surname>Furberg</surname><given-names>CD</given-names></string-name>, <string-name><surname>Saklayen</surname><given-names>MG</given-names></string-name>, <string-name><surname>Thadani</surname><given-names>U</given-names></string-name>, <string-name><surname>Probstfield</surname><given-names>JL</given-names></string-name>, <string-name><surname>Davis</surname><given-names>BR</given-names></string-name>. <article-title>Long‐term follow‐up of participants with heart failure in the Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)</article-title>. <source xml:lang="en">Circulation</source>. <year>2011</year>;<volume>124</volume>:<fpage>1811</fpage>–<lpage>1818</lpage>.<pub-id pub-id-type="pmid">21969009</pub-id></mixed-citation>
              </ref>
              <ref id="jah33961-bib-0018">
                <label>18</label>
                <mixed-citation publication-type="journal" id="jah33961-cit-0018"><string-name><surname>Schocken</surname><given-names>DD</given-names></string-name>, <string-name><surname>Benjamin</surname><given-names>EJ</given-names></string-name>, <string-name><surname>Fonarow</surname><given-names>GC</given-names></string-name>, <string-name><surname>Krumholz</surname><given-names>HM</given-names></string-name>, <string-name><surname>Levy</surname><given-names>D</given-names></string-name>, <string-name><surname>Mensah</surname><given-names>GA</given-names></string-name>, <string-name><surname>Narula</surname><given-names>J</given-names></string-name>, <string-name><surname>Shor</surname><given-names>ES</given-names></string-name>, <string-name><surname>Young</surname><given-names>JB</given-names></string-name>, <string-name><surname>Hong</surname><given-names>Y</given-names></string-name>. <article-title>Prevention of heart failure: a scientific statement from the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group</article-title>. <source xml:lang="en">Circulation</source>. <year>2008</year>;<volume>117</volume>:<fpage>2544</fpage>–<lpage>2565</lpage>.<pub-id pub-id-type="pmid">18391114</pub-id></mixed-citation>
              </ref>
              <ref id="jah33961-bib-0019">
                <label>19</label>
                <mixed-citation publication-type="journal" id="jah33961-cit-0019"><string-name><surname>Roush</surname><given-names>GC</given-names></string-name>, <string-name><surname>Buddharaju</surname><given-names>V</given-names></string-name>, <string-name><surname>Ernst</surname><given-names>ME</given-names></string-name>, <string-name><surname>Holford</surname><given-names>TR</given-names></string-name>. <article-title>Chlorthalidone: mechanisms of action and effect on cardiovascular events</article-title>. <source xml:lang="en">Curr Hypertens Rep</source>. <year>2013</year>;<volume>15</volume>:<fpage>514</fpage>–<lpage>521</lpage>.<pub-id pub-id-type="pmid">23839110</pub-id></mixed-citation>
              </ref>
              <ref id="jah33961-bib-0020">
                <label>20</label>
                <mixed-citation publication-type="journal" id="jah33961-cit-0020"><string-name><surname>Cacciapuoti</surname><given-names>F</given-names></string-name>. <article-title>Molecular mechanisms of left ventricular hypertrophy (LVH) in systemic hypertension (SH)—possible therapeutic perspectives</article-title>. <source xml:lang="en">J Am Soc Hypertens</source>. <year>2011</year>;<volume>5</volume>:<fpage>449</fpage>–<lpage>455</lpage>.<pub-id pub-id-type="pmid">22015318</pub-id></mixed-citation>
              </ref>
              <ref id="jah33961-bib-0021">
                <label>21</label>
                <mixed-citation publication-type="journal" id="jah33961-cit-0021"><string-name><surname>Ernst</surname><given-names>ME</given-names></string-name>, <string-name><surname>Davis</surname><given-names>BR</given-names></string-name>, <string-name><surname>Soliman</surname><given-names>EZ</given-names></string-name>, <string-name><surname>Prineas</surname><given-names>RJ</given-names></string-name>, <string-name><surname>Okin</surname><given-names>PM</given-names></string-name>, <string-name><surname>Ghosh</surname><given-names>A</given-names></string-name>, <string-name><surname>Cushman</surname><given-names>WC</given-names></string-name>, <string-name><surname>Einhorn</surname><given-names>PT</given-names></string-name>, <string-name><surname>Oparil</surname><given-names>S</given-names></string-name>, <string-name><surname>Grimm</surname><given-names>RH</given-names><suffix>Jr</suffix></string-name>; <collab collab-type="authors">Group ACR</collab>
. <article-title>Electrocardiographic measures of left ventricular hypertrophy in the antihypertensive and lipid‐lowering treatment to prevent heart attack trial</article-title>. <source xml:lang="en">J Am Soc Hypertens</source>. <year>2016</year>;<volume>10</volume>:<fpage>930</fpage>–<lpage>938</lpage>.<pub-id pub-id-type="pmid">27938852</pub-id></mixed-citation>
              </ref>
              <ref id="jah33961-bib-0022">
                <label>22</label>
                <mixed-citation publication-type="journal" id="jah33961-cit-0022"><string-name><surname>Jain</surname><given-names>A</given-names></string-name>, <string-name><surname>Tandri</surname><given-names>H</given-names></string-name>, <string-name><surname>Dalal</surname><given-names>D</given-names></string-name>, <string-name><surname>Chahal</surname><given-names>H</given-names></string-name>, <string-name><surname>Soliman</surname><given-names>EZ</given-names></string-name>, <string-name><surname>Prineas</surname><given-names>RJ</given-names></string-name>, <string-name><surname>Folsom</surname><given-names>AR</given-names></string-name>, <string-name><surname>Lima</surname><given-names>JA</given-names></string-name>, <string-name><surname>Bluemke</surname><given-names>DA</given-names></string-name>. <article-title>Diagnostic and prognostic utility of electrocardiography for left ventricular hypertrophy defined by magnetic resonance imaging in relationship to ethnicity: the Multi‐Ethnic Study of Atherosclerosis (MESA)</article-title>. <source xml:lang="en">Am Heart J</source>. <year>2010</year>;<volume>159</volume>:<fpage>652</fpage>–<lpage>658</lpage>.<pub-id pub-id-type="pmid">20362725</pub-id></mixed-citation>
              </ref>
              <ref id="jah33961-bib-0023">
                <label>23</label>
                <mixed-citation publication-type="journal" id="jah33961-cit-0023"><string-name><surname>Leigh</surname><given-names>JA</given-names></string-name>, <string-name><surname>O'Neal</surname><given-names>WT</given-names></string-name>, <string-name><surname>Soliman</surname><given-names>EZ</given-names></string-name>. <article-title>Electrocardiographic left ventricular hypertrophy as a predictor of cardiovascular disease independent of left ventricular anatomy in subjects aged &gt;/=65 years</article-title>. <source xml:lang="en">Am J Cardiol</source>. <year>2016</year>;<volume>117</volume>:<fpage>1831</fpage>–<lpage>1835</lpage>.<pub-id pub-id-type="pmid">27067620</pub-id></mixed-citation>
              </ref>
              <ref id="jah33961-bib-0024">
                <label>24</label>
                <mixed-citation publication-type="journal" id="jah33961-cit-0024"><string-name><surname>Oseni</surname><given-names>AO</given-names></string-name>, <string-name><surname>Qureshi</surname><given-names>WT</given-names></string-name>, <string-name><surname>Almahmoud</surname><given-names>MF</given-names></string-name>, <string-name><surname>Bertoni</surname><given-names>AG</given-names></string-name>, <string-name><surname>Bluemke</surname><given-names>DA</given-names></string-name>, <string-name><surname>Hundley</surname><given-names>WG</given-names></string-name>, <string-name><surname>Lima</surname><given-names>JA</given-names></string-name>, <string-name><surname>Herrington</surname><given-names>DM</given-names></string-name>, <string-name><surname>Soliman</surname><given-names>EZ</given-names></string-name>. <article-title>Left ventricular hypertrophy by ECG versus cardiac MRI as a predictor for heart failure</article-title>. <source xml:lang="en">Heart</source>. <year>2017</year>;<volume>103</volume>:<fpage>49</fpage>–<lpage>54</lpage>.<pub-id pub-id-type="pmid">27486144</pub-id></mixed-citation>
              </ref>
              <ref id="jah33961-bib-0025">
                <label>25</label>
                <mixed-citation publication-type="journal" id="jah33961-cit-0025"><string-name><surname>Bang</surname><given-names>CN</given-names></string-name>, <string-name><surname>Devereux</surname><given-names>RB</given-names></string-name>, <string-name><surname>Okin</surname><given-names>PM</given-names></string-name>. <article-title>Regression of electrocardiographic left ventricular hypertrophy or strain is associated with lower incidence of cardiovascular morbidity and mortality in hypertensive patients independent of blood pressure reduction—a LIFE review</article-title>. <source xml:lang="en">J Electrocardiol</source>. <year>2014</year>;<volume>47</volume>:<fpage>630</fpage>–<lpage>635</lpage>.<pub-id pub-id-type="pmid">25052475</pub-id></mixed-citation>
              </ref>
              <ref id="jah33961-bib-0026">
                <label>26</label>
                <mixed-citation publication-type="journal" id="jah33961-cit-0026"><string-name><surname>Tereshchenko</surname><given-names>LG</given-names></string-name>, <string-name><surname>McNitt</surname><given-names>S</given-names></string-name>, <string-name><surname>Han</surname><given-names>L</given-names></string-name>, <string-name><surname>Berger</surname><given-names>RD</given-names></string-name>, <string-name><surname>Zareba</surname><given-names>W</given-names></string-name>. <article-title>ECG marker of adverse electrical remodeling post‐myocardial infarction predicts outcomes in MADIT II study</article-title>. <source xml:lang="en">PLoS One</source>. <year>2012</year>;<volume>7</volume>:<fpage>e51812</fpage>.<pub-id pub-id-type="pmid">23251630</pub-id></mixed-citation>
              </ref>
              <ref id="jah33961-bib-0027">
                <label>27</label>
                <mixed-citation publication-type="journal" id="jah33961-cit-0027"><string-name><surname>Biering‐Sorensen</surname><given-names>T</given-names></string-name>, <string-name><surname>Kabir</surname><given-names>M</given-names></string-name>, <string-name><surname>Waks</surname><given-names>JW</given-names></string-name>, <string-name><surname>Thomas</surname><given-names>J</given-names></string-name>, <string-name><surname>Post</surname><given-names>WS</given-names></string-name>, <string-name><surname>Soliman</surname><given-names>EZ</given-names></string-name>, <string-name><surname>Buxton</surname><given-names>AE</given-names></string-name>, <string-name><surname>Shah</surname><given-names>AM</given-names></string-name>, <string-name><surname>Solomon</surname><given-names>SD</given-names></string-name>, <string-name><surname>Tereshchenko</surname><given-names>LG</given-names></string-name>. <article-title>Global ECG measures and cardiac structure and function: the ARIC study (Atherosclerosis Risk in Communities)</article-title>. <source xml:lang="en">Circ Arrhythm Electrophysiol</source>. <year>2018</year>;<volume>11</volume>:<fpage>e005961</fpage>.<pub-id pub-id-type="pmid">29496680</pub-id></mixed-citation>
              </ref>
              <ref id="jah33961-bib-0028">
                <label>28</label>
                <mixed-citation publication-type="journal" id="jah33961-cit-0028"><string-name><surname>Davis</surname><given-names>BR</given-names></string-name>, <string-name><surname>Furberg</surname><given-names>CD</given-names></string-name>, <string-name><surname>Wright</surname><given-names>JT</given-names><suffix>Jr</suffix></string-name>, <string-name><surname>Cutler</surname><given-names>JA</given-names></string-name>, <string-name><surname>Whelton</surname><given-names>P</given-names></string-name>. <article-title>ALLHAT: setting the record straight</article-title>. <source xml:lang="en">Ann Intern Med</source>. <year>2004</year>;<volume>141</volume>:<fpage>39</fpage>–<lpage>46</lpage>.<pub-id pub-id-type="pmid">15238369</pub-id></mixed-citation>
              </ref>
              <ref id="jah33961-bib-0029">
                <label>29</label>
                <mixed-citation publication-type="journal" id="jah33961-cit-0029"><string-name><surname>Proschan</surname><given-names>M</given-names></string-name>, <string-name><surname>Ford</surname><given-names>CE</given-names></string-name>, <string-name><surname>Cutler</surname><given-names>JA</given-names></string-name>, <string-name><surname>Graumlich</surname><given-names>JF</given-names></string-name>, <string-name><surname>Pavlik</surname><given-names>V</given-names></string-name>, <string-name><surname>Cushman</surname><given-names>WC</given-names></string-name>, <string-name><surname>Davis</surname><given-names>BR</given-names></string-name>, <string-name><surname>Alderman</surname><given-names>MH</given-names></string-name>, <string-name><surname>Gordon</surname><given-names>D</given-names></string-name>, <string-name><surname>Furberg</surname><given-names>CD</given-names></string-name>, <string-name><surname>Franklin</surname><given-names>SS</given-names></string-name>, <string-name><surname>Blumenthal</surname><given-names>SS</given-names></string-name>, <string-name><surname>Castaldo</surname><given-names>RS</given-names></string-name>, <string-name><surname>Preston</surname><given-names>RA</given-names></string-name>; <collab collab-type="authors">LHAT Collaborative Research Group</collab>
. <article-title>How much effect of different antihypertensive medications on cardiovascular outcomes is attributable to their effects on blood pressure?</article-title>
<source xml:lang="en">Stat Med</source>. <year>2013</year>;<volume>32</volume>:<fpage>884</fpage>–<lpage>897</lpage>.<pub-id pub-id-type="pmid">22961832</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
